



APASL STC 2023 BUSAN

Asian Pacific Association for the Study of the Liver Single Topic Conference

“Toward Elimination of Viral Hepatitis”

September 21-23, 2023 | BEXCO, Busan, Korea

Please scan the QR Codes below for downloading
the abstract book and program book.



Abstract Book



Program Book



APASL



The Korean Association
for the Study of the Liver


APASL STC 2023 BUSAN


Asian Pacific Association for the Study of the Liver Single Topic Conference

“Toward Elimination of Viral Hepatitis”

September 21-23, 2023 | BEXCO, Busan, Korea

- 01 Welcome Message
- 02 Organizing Committee
- 03 Our Partners
- 04 APASL
- 06 Floor Plan
- 07 Industrial Exhibition Floor Plan
- 08 General Information
- 10 Scientific Program
 - [Day 1] Program at a Glance
 - Scientific Program
 - [Day 2] Program at a Glance
 - Scientific Program
 - [Day 3] Program at a Glance
 - Scientific Program
- 26 Luncheon Industry Symposia
- 27 Free Paper Presentation
- 28 Oral Poster Presentation
- 30 Poster Exhibition
- 53 Transportation
- 55 Booth Tour





The Korean Association
for the Study of the Liver

Toward Elimination of Viral Hepatitis: Achievements, Challenges, and Prospects

Welcome Message

Dear Colleagues and Friends,

On behalf of the Organizing Committee, we would like to welcome you to the APASL STC 2023, which is held in Busan, Korea from September 21st to the 23rd, 2023. Building on the success of previous meetings of the APASL, we shaped the program with the theme "Toward Elimination of Viral Hepatitis," an excellent opportunity for you to learn and discuss the latest research results alongside world renowned medical professionals.

The three-day scientific program and presentations delivered by leading world experts, as well as new research by young scientists, will provide a perfect blend of both basic and clinical research. Regardless of your personal expertise, this meeting will allow you to share opinions and contact experts from multiple areas of Viral Hepatitis research. To this aim, several tracks have been identified with the meeting program designed to facilitate contacts with several opinion leaders who will guarantee the highest possible scientific level of expertise-ensuring new developments for the elimination of Viral Hepatitis.

The conference venue of Busan, the second largest city of Korea, is now officially bidding for the World EXPO 2030. It offers numerous dynamic features to welcome you following the challenging COVID pandemic, and, therefore, we hope you enjoy meeting with your colleagues from around the world and have a wonderful, memorable experience in terms of both scientific and social experience.

Thank you, and we look forward to your active participation.

Sincerely,



Dong Jin Suh
Honorary Chairman



Jin Mo Yang
Honorary Chairman



Si Hyun Bae
President



The Korean Association
for the Study of the Liver

Organizing Committee of APASL STC 2023 BUSAN

APASL STC 2023 Busan Organizing Committee		
Honorary Chairman	Dong Jin Suh	<i>Daehang Hospital</i>
	Jin Mo Yang	<i>The Catholic Univ. of Korea</i>
President	Si Hyun Bae	<i>The Catholic Univ. of Korea</i>
Secretary General	Sang Hoon Ahn	<i>Yonsei Univ.</i>
Vice Secretary General	Ju Hyun Shim	<i>Univ. of Ulsan</i>
	Jun Yong Park	<i>Yonsei Univ.</i>
Chair, Scientific Committee	Jeong Won Jang	<i>The Catholic Univ. of Korea</i>
Chair, Publication Committee	Seung Up Kim	<i>Yonsei Univ.</i>
Chair, Social Program Committee	Ji Hoon Kim	<i>Korea Univ.</i>
Chair, Protocol Committee	Young Kul Jung	<i>Korea Univ.</i>
Chair, International Liaison Committee	Won Kim	<i>Seoul National Univ.</i>
Chair, Planning Committee	Hyung Joon Kim	<i>Chung-Ang Univ.</i>
Chair, Financial Committee	Do Young Kim	<i>Yonsei Univ.</i>
	Jung Hyun Kwon	<i>The Catholic Univ. of Korea</i>
Chair, Promotion Committee	Myeong Jun Song	<i>The Catholic Univ. of Korea</i>
Chair, Exhibition Committee	Yeon Seok Seo	<i>Korea Univ.</i>
Chair, Public Relations Committee	Won Hyeok Choe	<i>Konkuk Univ.</i>
Chair, Informatics Committee	Eun Young Cho	<i>Wonkwang Univ.</i>
Chair, Registration Committee	Jae Young Jang	<i>Soonchunhyang Univ.</i>

Scientific Committee Members	
Jeong Won Jang (Chair)	<i>The Catholic Univ. of Korea</i>
Jung Hyun Kwon	<i>The Catholic Univ. of Korea</i>
Eun Young Cho	<i>Wonkwang Univ.</i>
Won Sohn	<i>Sungkyunkwan Univ.</i>
Hye Won Lee	<i>Yonsei Univ.</i>
Pil Soo Sung	<i>The Catholic Univ. of Korea</i>
Jeong Eun Song	<i>Daegu Catholic Univ.</i>
Kyun-Hwan Kim	<i>Sungkyunkwan Univ.</i>
Eui-Cheol Shin	KAIST
Moon Young Kim	<i>Yonsei Univ. Wonju</i>
Su Jong Yu	<i>Seoul National Univ.</i>
Young-Joo Jin	<i>Inha Univ.</i>
Jung Gil Park	<i>Yeungnam Univ.</i>
Sun Young Yim	<i>Korea Univ.</i>
Jonggi Choi	<i>Univ. of Ulsan</i>

Publication Committee Members	
Seung Up Kim (Chair)	<i>Yonsei Univ.</i>
Minjong Lee	<i>Ewha Womans Univ.</i>
Yuri Cho	<i>National Cancer Center</i>
Han Ah Lee	<i>Ewha Womans Univ.</i>
Jung Hwan Yu	<i>Inha Univ.</i>
Young Chang	<i>Soonchunhyang Univ.</i>
Ji Won Han	<i>The Catholic Univ. of Korea</i>
Eun Ju Cho	<i>Seoul National Univ.</i>

Social Program & Protocol Committee Members	
Ji Hoon Kim (Chair)	<i>Korea Univ.</i>
Young Kul Jung (Chair)	<i>Korea Univ.</i>
Ju-Yeon Cho	<i>Chosun Univ.</i>
Yeonjung Ha	<i>CHA Univ.</i>
Sun Young Yim	<i>Korea Univ.</i>

APASL STC 2023 BUSAN

September 21-23, 2023 | BEXCO, Busan, Korea

*APASL STC 2023 Busan is proud to introduce our partners.
We value your patronage and appreciate your confidence in us.*

Partner Companies

Diamond	 YUHAN	 GILEAD	
Platinum Elite			
Gold	 DAEWOONG	 CELLTRION	
Silver			
Bronze	 GC	 Samil	
	BORYUNG		

Partner Government Agencies



APASL History



Ever since its inception, in August 1978 in Singapore, APASL (Asian Pacific Association for the Study of the Liver) never looks back but stick to its goal towards advancing the science and practice of Hepatology.

Today it is one of the leading associations based on investigation and treatment of liver diseases in the world and the largest scientific body that upholds the standards and profession, research and create improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region.

APASL's main objectives are to promote the latest scientific advancement and education of hepatology science, exchange of information and the development of consensus, encourage the practice of medicine in liver diseases and also coordinate scientific studies between various scientists and clinicians throughout the region.

We hold scientific educational symposia/ conferences developed by leading hepatologists periodically. Our events feature expert speakers presenting the finest data in the most happening topics of liver diseases with high quality scientific technical presentations, followed by varied supporting program.

Each of our events intended to meet the growing demands of hepatology as core medical specialty and offers participants the right platform to exchange research, discuss outcomes, and interact with colleagues, focused on liver diseases.

Our members include all medical professionals dedicated to hepatology — its research, practice and care. We cover the region from Manchuria in the North, to Australia in the South, to the Pacific Islands in the East and Turkey in the West. Our members are elected on their documented scientific publications. Mentoring, sharing of knowledge and dedication to professional growth and development are among the core values of APASL and its members.



APASL

Steering Committee

Chairman	Shiv K Sarin	New Delhi
President	Shuichiro Shiina	Tokyo
Immediate Past President	Han-Chieh Lin	Taipei
President Elect	Lai Wei	Beijing
Secretary General-cum-Treasurer	Manoj K Sharma	New Delhi
Past Presidents	Laurentius A. Lesmana	Jakarta
	Jose Sollano	Manila
	Masao Omata	Tokyo
	Dong Jin Suh	Seoul
	George Lau	Hong Kong
	Ji-Dong Jia	Beijing
	Teerha Piratvisuth	Hat-Yai
	Jia-Horng Kao	Taipei
	Darrell Crawford	Brisbane
	A. Kadir Dokmeci	Ankara
	Osamu Yokosuka	Chiba
	Jinlin Hou	Guangzhou
	Barjesh C. Sharma	New Delhi
	Diana A. Payawal	Manila
Rino Gani	Jakarta	
Tawesak Tanwandee	Bangkok	
Jin Mo Yang	Seoul	
Ethics and Guidelines Committee	Barjesh C. Sharma	New Delhi
Finance Committee	A. Kadir Dokmeci	Ankara
International Liaison	Shiv K Sarin	New Delhi
Scientific Program Committee	Osamu Yokosuka	Chiba

Executive Council

President	Shuichiro Shiina	Tokyo
Immediate Past President	Han-Chieh Lin	Taipei
President Elect	Lai Wei	Beijing
Secretary General-cum-Treasurer	Manoj Kumar Sharma	New Delhi
Executive Council	Gulnara Aghayeva	Baku
	Chun-Jen Liu	Taipei
	Mamun-Al-Mahtab	Dhaka
	Rakhi Maiwall	New Delhi
	Yoshiyuki Ueno	Yamagata
	Sang Hoon Ahn	Seoul
	Elizabeth Powell	Brisbane
	Jian Zhou	Shanghai

Floor Plan

1F

ROOM 1


- Opening Ceremony (Sept. 21)
- Closing & Award Ceremony (Sept. 23)
- Lucky Draw (Sept. 21-23)

Day 1. September 21, 2023

Luncheon Symposium 1 

Day 2. September 22, 2023

Luncheon Symposium 4 



ROOM 2

Day 1. September 21, 2023

Luncheon Symposium 2 

Day 2. September 22, 2023

Luncheon Symposium 5 

ROOM 3

Day 1. September 21, 2023


Luncheon Symposium 3 

Day 2. September 22, 2023

Luncheon Symposium 6 

2F

3F




★ QR Code Scanner

Industrial Exhibition Floor Plan



2F

3F



1	Abbvie
2	Daewoong
3	Celltrion
4	GC
5	Roche
6	Eisai
7	Astellas
8	Samil
9	Dona-A ST
10	Boryung
11	Sysmex
12	CKD
13	Bukwang
14	Hanmi
15	PharmaKing
16	Ildong
17	Han Wha

General Information

APASL STC 2023 BUSAN

- Date September 21-23, 2023
- Venue BEXCO, Busan, Korea
- Theme Toward Elimination of Viral Hepatitis: Achievements, Challenges, and Prospects
- Official Language English
- Official Website www.apaslstc2023busan.org
- Hosted by
 - Asian Pacific Association for the Study of the Liver (APASL)
 - Organizing Committee of the Asian Pacific Association for the Study of the Liver Single Topic Conference 2023 Busan (APASL STC 2023 Busan)
 - The Korean Association for the Study of the Liver (KASL)

Registration Desk

Lobby (1F)

- September 21 07:30-18:00
- September 22 06:30-18:00
- September 23 06:30-12:30

Participants will receive their name badges when collecting their meeting materials on site. Participants are required to wear their name badges during all meeting events.

Opening Ceremony

Room 1 (1F)

- September 21 10:00-10:20

Award Ceremony & Closing

Room 1 (1F)

- September 23 11:50-12:20

Meal

Breakfast (All Participant)

Breakfast will be provided during Early Morning Sessions.

Lunch (All Participant)

A lunch box will be served during the industry symposium. There will be 6 different industry luncheon symposiums held from Sept. 21-22 during lunch time. Please check their agenda in the program book and join the symposium as per your preference.

Faculty Dinner (Invitation Only)

September 22 18:30-20:00, Nurimaru APEC House
Coach service will be arranged from BEXCO to Nurimaru APEC House. Please come to the main lobby (1F) by 17:50.

BEXCO, Convention Hall



General Information

Poster Presentation

Poster Exhibition Room 4 (3F)

- September 21 10:30-17:40
- September 22 08:30-17:40
- September 23 08:30-12:20

Oral Poster Presentation Lobby (3F)

- September 21 10:50-11:50 / 13:20-14:20
- September 22 08:30-09:30 / 09:30-10:30

Faculty Lounge & Speaker Ready Room (Preview Room) (1F)

- September 21 07:30-17:40
- September 22 07:30-17:40 (EMW: 07:00)
- September 23 07:30-12:20 (EMW: 07:00)

All presenters are requested to come to the Preview Room at least 1 hour in advance of the presentations to verify if the data function properly on the equipment provided.

Industrial Exhibition Internet Lounge

Room 4 (3F)

- September 21 08:30-17:40
- September 22 08:30-17:40
- September 23 08:30-12:20

Café APASL STC 2023 Busan Luggage Storage Service

Room 4 (3F)
Lobby (3F)

- September 21 08:30-17:40
- September 22 08:30-17:40
- September 23 08:30-12:20

APASL STC 2023 BUSAN 평점 안내




	21일 (목)	22일 (금)	23일 (토)
대한의사협회	6점	6점	3점
대한내과학회 평생교육	1점	1점	1점
대한내과학회 분과전문의 연수교육		* 3점	
		* 3점	

평점을 위해서 매일 최초 입실 및 최종 퇴실 시 (총 2회 이상) 바코드를 인식시켜 주셔야 합니다.

* 9월 22일(금) 진행되는 전공의 및 전임의를 위한 특별세션 "Hepatology Associate - Education Forum"을 수강하실 경우 추가평점이 주어집니다. (본 평점을 위해서는 해당 강의실 앞에 설치된 QR 기기를 통해 명찰을 꼭 인식시켜 주시기 바랍니다.)

Program at a Glance

DAY 1 September 21, 2023

TIME	ROOM 1 (1F)	ROOM 2 (2F)	ROOM 3 (2F)	ROOM 4 (3F)
07:00-08:00				
09:00-10:00	Pre-Congress Symposium			
10:00-10:30	Opening Ceremony			
10:30-11:00	President's Choice Lecture			Poster Viewing
11:00-12:00	Symposium 1-1	Joint Symposium (East Asia)		Oral Poster Presentation 1
12:00-13:00	Luncheon Symposium 1 abbvie	Luncheon Symposium 2 	Luncheon Symposium 3 	Poster Viewing
13:00-14:00	State-of-the-Art Lecture I			
14:00-15:00	Keynote Lecture 1		SIG 1	Oral Poster Presentation 2
15:00-16:00	Coffee Break			
16:00-17:00	PG Course 1	Symposium 1-2		Poster Viewing
17:00-18:00	Coffee Break			
18:00-19:00	PG Course 2	Symposium 1-3	Policy Session 	
19:00-20:00				

Scientific Program

ROOM 1 (1F)

September 21, 2023

08:30-09:50 Pre-Congress Symposium

*Byung Ik Kim (Sungkyunkwan Univ., Korea)
Young Oh Kweon (Kyungpook National Univ., Korea)
Youn-Jae Lee (Inje Univ., Korea)*

08:30-08:40 Updates on Epidemiology and Natural Course of Viral Hepatitis in Asian-Pacific Region: HBV
Jeong Eun Song (Daegu Catholic Univ., Korea)

08:40-08:50 Updates on Epidemiology and Natural Course of Viral Hepatitis in Asian-Pacific Region: HCV
Nae-Yun Heo (Inje Univ., Korea)

08:50-09:00 Clinical Impacts of Epidemiological Growth of NAFLD in Asian-Pacific Region
Young Youn Cho (Chung-Ang Univ., Korea)

09:00-09:10 Cure of Viral Hepatitis: Definition and Sub-Classification
Hyun Young Woo (Pusan National Univ., Korea)

09:10-09:20 Overview of Barriers to HBV Cure
Eun Young Cho (Wonkwang Univ., Korea)

09:20-09:40 Overview of Barriers to HCV Cure
Tae-Hee Lee (Konyang Univ., Korea)

09:40-09:50 Discussion

10:00-10:20 Opening Ceremony

10:20-10:50 President's Choice Lecture

Si Hyun Bae (The Catholic Univ. of Korea, Korea)

10:20-10:50 A Bold Plan to Eliminate Liver Disease
W. Ray Kim (Stanford Univ., USA)

10:50-11:50 Symposium 1-1. Hepatitis Elimination by 2030: Where Are We Now?

*Diana A. Payawal (Fatima Medical Univ., Philippines)
Dong Jin Suh (Daehang Hospital, Korea)*

10:50-11:05 HBV 2023: New Therapeutic Strategies against an Old Foe
Sang Hoon Ahn (Yonsei Univ., Korea)

11:05-11:20 HCV 2023: The Road to Elimination of HCV
Yasuhito Tanaka (Kumamoto Univ., Japan)

 Pre-Recorded Lecture

11:20-11:35 Optimizing Hepatitis B and C Treatment in Resource-Limited Settings
Diana A. Payawal (Fatima Medical Univ., Philippines)

11:35-11:50 Global Care Cascade for Chronic Hepatitis B and C Virus Infection
Ming-Lung Yu (National Sun Yat-sen Univ., Taiwan)

11:50-12:50 Luncheon Symposium 1 **abbvie**

12:50-13:20 State-of-the-Art Lecture 1

Masao Omata (The Univ. of Tokyo, Japan)

12:50-13:20 A 30-Year Journey of HCV Research: From Discovery to a Cure
Raymond T. Chung (Harvard Univ., USA)

13:20-14:20	Keynote Lecture 1. Viral Hepatitis Elimination: Where Do We Stand? It Has Already Reached Halfway by 2030	<i>Chun-Jen Liu (National Taiwan Univ., Taiwan) Kwang Cheol Koh (Sungkyunkwan Univ., Korea)</i>
13:20-13:40	Notable Milestones Achieved towards Viral Hepatitis Elimination to Date	<i>Jose D. Sollano (The Univ. of Santo Tomas, Philippines)</i>
13:40-14:00	Efforts and Strategy to Accelerate Progress towards Viral Hepatitis Elimination by 2030	<i>Jinlin Hou (Southern Medical Univ., China)</i>
		 Pre-Recorded Lecture
14:00-14:20	It Is Time for a Simplified Approach to Hepatitis B Elimination	<i>Young-Suk Lim (Univ. of Ulsan, Korea)</i>
14:20-14:40	Coffee Break	
14:40-16:00	PG Course 1. On the Way to HBV Elimination, What Is a Recent Issue?	<i>Marc G. Ghany (NIH, USA) George Lau (Humanity and Health Medical Group, Hong Kong) Kwang-Hyub Han (CHA Univ., Korea)</i>
14:40-15:00	When to Stop Nucleos(t)ide Analogues: Risks and Benefits	<i>Jordan Feld (Univ. of Toronto, Canada)</i>
15:00-15:20	Application of Current Biomarkers to Guide Anti-HBV Treatment	<i>Tetsuya Hosaka (Toranomon Hospital, Japan)</i>
15:20-15:40	Can Antivirals Reduce Intrahepatic cccDNA and Integrated HBV DNA?	<i>Marc G. Ghany (NIH, USA)</i>
15:40-16:00	Risk of HCC and Biomarkers after a Cure of Hepatitis B	<i>Jeong Won Jang (The Catholic Univ. of Korea, Korea)</i>
16:00-16:20	Coffee Break	
16:20-17:40	PG Course 2. Treatment of Viral Hepatitis, What Progress Being Made?	<i>Raymond T. Chung (Harvard Univ., USA) Ming-Lung Yu (National Sun Yat-sen Univ., Taiwan) Jin Mo Yang (The Catholic Univ. of Korea, Korea)</i>
16:20-16:40	Current Optimal Treatment for Chronic HCV Infection in Various Clinical Situations	<i>Jung Il Lee (Yonsei Univ., Korea)</i>
16:40-17:00	Strategies for the Elimination of Hepatitis C	<i>Norah Terrault (Univ. of Southern California, USA)</i>
17:00-17:20	Current and Emerging Therapeutic Approaches to HDV Infection	<i>Maria Buti Ferret (Hospital Universitario Valle Hebron, Spain)</i>
17:20-17:40	HBV-HCV Dual Infection: Changing Epidemiology and Treatment in Asia	<i>Chun-Jen Liu (National Taiwan Univ., Taiwan)</i>

10:50-11:50	Joint Symposium (East Asia): HCV Elimination	<i>Lai Wei (Tsinghua Univ., China)</i> <i>Masao Omata (The Univ. of Tokyo, Japan)</i> <i>Sook-Hyang Jeong (Seoul National Univ., Korea)</i>
10:50-11:00	Cost-Effectiveness of HCV Screening in Korea: A Step towards HCV Elimination <i>Sook-Hyang Jeong (Seoul National Univ., Korea)</i>	
11:00-11:10	Clinical Challenges in HCV Management in Japan <i>Atsumasa Komori (Nagasaki Univ., Japan)</i>	
11:10-11:20	How Would China Achieve WHO's Target of Eliminating HCV by 2030? <i>Lai Wei (Tsinghua Univ., China)</i>	
11:20-11:30	Linkage-to-Care and Follow-Up Strategy for HCV Infection in Taiwan <i>Tai-Chung Tseng (National Taiwan Univ., Taiwan)</i>	
11:30-11:50	Discussion	
11:50-12:50	Luncheon Symposium 2 	
14:40-16:00	Symposium 1-2. Immunology and Immunotherapy of Viral Hepatitis	<i>Hideki Ueno (Kyoto Univ., Japan)</i> <i>Eui-Cheol Shin (KAIST, Korea)</i>
14:40-15:00	Immunological Profile of Chronic HBV Infection: Can It Help to Improve Therapeutic Success? <i>Antonio Bertoletti (Duke-NUS Medical School, Singapore)</i>	
15:00-15:20	Immunological Scar after HCV Clearance <i>Eui-Cheol Shin (KAIST, Korea)</i>	
15:20-15:40	T-Cell Responses against Human Coronaviruses in Human Liver <i>Hideki Ueno (Kyoto Univ., Japan)</i>	
15:40-16:00	Novel Immunological Therapeutics for Cure of HBV Infection <i>Wonseok Kang (Sungkyunkwan Univ., Korea)</i>	
16:00-16:20	Coffee Break	
16:20-17:40	Symposium 1-3. Emerging Antivirals for HBV Cure	<i>Jidong Jia (Capital Medical Univ., China)</i> <i>Seong Gyu Hwang (CHA Univ., Korea)</i>
16:20-16:40	Updates on Drugs for HBV Entry and Post-Entry Inhibition <i>Hyung Joon Yim (Korea Univ., Korea)</i>	
16:40-17:00	Updates on HBV Capsid Assembly Inhibitors <i>Robert G. Gish (Hepatitis B Foundation, USA)</i>	
17:00-17:20	Updates on Drugs Targeting HBV RNAs: ASOs and siRNA <i>Jidong Jia (Capital Medical Univ., China)</i>	
17:20-17:40	Updates on cccDNA Disruptors <i>Jin-Wook Kim (Seoul National Univ., Korea)</i>	

Scientific Program

ROOM 3 (2F)

September 21, 2023

11:50-12:50 Luncheon Symposium 3 

13:20-14:20 SIG 1. Diagnostic and Therapeutic Targets for Virus-Associated HCC *Chul Ju Han (Korea Cancer Center Hospital, Korea)
Won Young Tak (Kyungpook National Univ., Korea)*

13:20-13:35 Novel Blood-Based Biomarkers for Diagnosis of HCC in Chronic Viral Hepatitis
Jaeyoun Cheong (Ajou Univ., Korea)

13:35-13:50 TERT Alterations in Virus-Induced Hepatocarcinogenesis: An Actionable Target?
Ju Hyun Shim (Univ. of Ulsan, Korea)

13:50-14:05 Molecular Signature and Immune Landscape of among HBV, HCV, and Non-Viral HCCs
Young-Sun Lee (Korea Univ. Korea)

14:05-14:20 Differential T-Cell Function between Viral and Non-Viral HCC during Immuno-Oncologic Therapy
Ji Won Han (The Catholic Univ. of Korea, Korea)

14:20-14:40 Coffee Break

16:20-17:40 Policy Session  *Young-Suk Lim (Univ. of Ulsan, Korea)
Jae Young Jang (Soonchunhyang Univ., Korea)*

16:20-16:35 Introduction of the 1st National Strategic Plan for Viral Hepatitis B and C Control (2023-2027)
Jin Seon Yang (Korea Disease Control and Prevention Agency, Korea)

16:35-16:50 Hepatitis B and C Elimination Strategy in Korea
Chang Hun Lee (Jeonbuk National Univ., Korea)

16:50-17:05 Korean HCV Cohort Study and People Who Inject Drugs (PWID) in Korea
Gwang Hyeon Choi (Seoul National Univ., Korea)







17:05-17:20 Korean HBV Cohort Study
Jun Yong Park (Yonsei Univ., Korea)

17:20-17:40 Panel Discussion
Speakers & Panelists: In Hee Kim (Jeonbuk National Univ., Korea), Young Chang (Soonchunhyang Univ., Korea)

 Session in Korean

Program at a Glance

DAY 2 September 22, 2023


TIME	ROOM 1 (1F)	ROOM 2 (2F)	ROOM 3-1 (2F)	ROOM 3-2 (2F)	ROOM 4 (3F)	
07:00-08:00						
			EMW 1	EMW 2		
09:00	Symposium 2-1	Symposium 2-2			Oral Poster Presentation 3	
10:00	Plenary Presentation	Symposium 2-3	SIG 2		Oral Poster Presentation 4	
Coffee Break						
11:00	Symposium 2-4	Symposium 2-5	SIG 3		Poster Viewing	
12:00	Luncheon Symposium 4  GILEAD	Luncheon Symposium 5  YUHAN	Luncheon Symposium 6  DAEWONG			
13:00	State-of-the-Art Lecture 2					
14:00	Keynote Lecture 2		Hepatology Associates Education Forum 1 			
Coffee Break						
15:00	APASL-AASLD Joint Symposium	Symposium 2-6	Hepatology Associates Education Forum 2 			
Coffee Break						
17:00	Symposium 2-7	Symposium 2-8	Hepatology Associates Education Forum 3 			
18:00						
19:00	Faculty Dinner (Invitation Only) Nurimaru APEC House					
20:00						


08:30-09:30	Symposium 2-1. Circulating HBV Markers: What Are Their Roles?	<i>Tarik Asselah (Hepatology at Hôpital Beaujon, France) Jung-Hwan Yoon (Seoul National Univ., Korea)</i>
08:30-08:50	Ultra-High Sensitivity HBsAg and Anti-HBc in Managing Chronic Hepatitis B	<i>Jihyun An (Hanyang Univ., Korea)</i>
08:50-09:10	HBcrAg and HBV RNA in Managing Chronic Hepatitis B	<i>Lung-Yi Mak (The Univ. of Hong Kong, Hong Kong)</i>
09:10-09:30	Circulating Virus-Host Chimera DNA for Monitoring Virus-Related HCC	<i>Shiou-Hwei Yeh (National Taiwan Univ., Taiwan)</i>
		 Pre-Recorded Lecture
09:30-10:30	Plenary Presentation	<i>Joo Hyun Sohn (Hanyang Univ., Korea), Jin-Wook Kim (Seoul National Univ., Korea)</i>
09:30-09:45	[P-01] The Epidemiology of Hepatitis B Virus Infection in an Endemic Region: A 15-Year Analysis and the Impact of COVID-19	<i>Jin Wook Park (Soonchunhyang Univ., Korea)</i>
09:45-10:00	[P-02] The Single-Cell Landscape Identifies Immunophenotyping and Tumor Microenvironments of HBV-Positive and Negative Hepatocellular Carcinoma	<i>Hongping Xia (National Cancer Center, Singapore)</i>
10:00-10:15	[P-03] An Increase in the Number of Activated Regulatory T-Cells Is Associated with an Improvement in Liver Function of Patients with Severe Alcoholic Hepatitis after Steroid Therapy	<i>Min Woo Kang (The Catholic Univ. of Korea, Korea)</i>
10:15-10:30	[P-04] Liver Failure versus Organ Failure in Acute on Chronic Liver Failure: Sequence and Consequence	<i>Young Chang (Soonchunhyang Univ., Korea)</i>
10:30-10:50	Coffee Break	
10:50-11:50	Symposium 2-4. Direction to Pursue in Hepatitis C Treatment	<i>Chun-Jen Liu (National Taiwan Univ., Taiwan) Seung Woon Paik (Sungkyunkwan Univ., Korea)</i>
10:50-11:05	How to Manage Patients with DAA Treatment Failure	<i>Young-Joo Jin (Inha Univ., Korea)</i>
11:05-11:20	How to Manage Difficult-to-Cure Patients: Decompensated Disease and Transplantation	<i>In Hee Kim (Jeonbuk National Univ., Korea)</i>
11:20-11:35	Managing Drug-Drug Interaction, Adherence, and Adverse Events in the Era of Pangenotypic DAA	<i>Woo Jin Chung (Keimyung Univ., Korea)</i>
11:35-11:50	Multidisciplinary Approach to Predict Fibrosis Progression and HCC after DAA Therapy	<i>Tawesak Tanwandee (Mahidol Univ., Thailand)</i>
11:50-12:50	Luncheon Symposium 4	

12:50-13:20	State-of-the-Art Lecture 2	<i>Jin Mo Yang (The Catholic Univ. of Korea, Korea)</i>
12:50-13:20	The Road to Curing Hepatitis B Virus Infection: Past, Present, and Future <i>George Lau (Humanity and Health Medical Group, Hong Kong)</i>	
13:20-14:20	Keynote Lecture 2. Cure of Viral Hepatitis. Is This Safe against the Development of HCC?	<i>Jia-Horng Kao (National Taiwan Univ., Taiwan) Kyung-Suk Suh (Seoul National Univ., Korea)</i>
13:20-13:40	Genetic Polymorphism and Family History as a Non-Modifiable Risk Factor for HCC after HBV Cure <i>Yoon Jun Kim (Seoul National Univ., Korea)</i>	
13:40-14:00	Viral Persistence after a Functional Cure and HCC Risk <i>Jia-Horng Kao (National Taiwan Univ., Taiwan)</i>	
14:00-14:20	Mechanisms of Hepatocarcinogenesis after HCV Eradication <i>Raymond T. Chung (Harvard Univ., USA)</i>	
14:20-14:40	Coffee Break	
14:40-16:00	APASL-AASLD Joint Symposium. A New Area of Interest in Chronic Hepatitis B: To Treat or Not to Treat	<i>Norah Terrault (Univ. of Southern California, USA) Si Hyun Bae (The Catholic Univ. of Korea, Korea)</i>
14:40-15:00	Classification and Clinical Characteristics of Gray-Zone in Chronic Hepatitis B <i>Marc G. Ghany (NIH, USA)</i>	
15:00-15:20	HBeAg-Positive "Gray-Zone": Should We Treat and Why? <i>Tai-Chung Tseng (National Taiwan Univ., Taiwan)</i>	
15:20-15:40	HBeAg-Negative "Gray-Zone": Should We Treat and Why? <i>Jordan Feld (Univ. of Toronto, Canada)</i>	
15:40-16:00	Optimizing Non-Invasive Methods to Identify Gray-Zone Patients with Liver Fibrosis <i>Seung Up Kim (Yonsei Univ., Korea)</i>	
16:00-16:20	Coffee Break	
16:20-17:40	Symposium 2-7. Debate Session. Strategies to Achieve HBsAg Seroclearance	<i>W. Ray Kim (Stanford Univ., USA) Maria Buti Ferret (Hospital Universitario Valle Hebron, Spain)</i>
16:20-16:35	Stopping Antivirals <i>Wen-Juei Jeng (Chang Gung Univ., Taiwan)</i>	
16:35-16:50	Continuing Antivirals <i>Jonggi Choi (Univ. of Ulsan, Korea)</i>	
16:50-17:05	Interferon or Interferon-Based Therapy <i>Tarik Asselah (Hepatology at Hôpital Beaujon, France)</i>	
17:05-17:20	Newer Antiviral Agents: Next Steps to Combination Therapy <i>Robert G. Gish (Hepatitis B Foundation, USA)</i>	
17:20-17:40	Discussion	


08:30-09:30	Symposium 2-2. Update of Cirrhosis and Portal Hypertension	<i>Shiv Kumar Sarin (Institute of Liver & Biliary Sciences, India)</i> <i>Dong Joon Kim (Hallym Univ., Korea)</i>
08:30-08:45	Liver and Spleen Stiffness for the Estimation of Portal Hypertension and Cirrhotic Complications	<i>Moon Young Kim (Yonsei Univ. Wonju, Korea)</i>
08:45-09:00	Antiviral Therapy and the Outcome of Patients with Decompensated Cirrhosis	<i>Sung-Eun Kim (Hallym Univ., Korea)</i>
09:00-09:15	Optimal Assessment and Improving Survival in Acute Variceal Bleeding	<i>Shiv Kumar Sarin (Institute of Liver & Biliary Sciences, India)</i>
09:15-09:30	The Role of Antibiotic Therapy in Acute Decompensation	<i>Jung Gil Park (Yeungnam Univ., Korea)</i>
09:30-10:30	Symposium 2-3. Non-B and Non-C Viral Hepatitis: Pathogenesis and Treatment	<i>Jaeseok Hwang (Keimyung Univ., Korea)</i> <i>Hee Bok Chae (Chungbuk National Univ., Korea)</i>
09:30-09:45	Immunopathogenesis of Acute Hepatitis A	<i>Eui-Cheol Shin (KAIST, Korea)</i>
09:45-10:00	Novel Therapies for Hepatitis D Virus	<i>Young Eun Chon (CHA Univ., Korea)</i>
10:00-10:15	Disease Burden and Potential Therapeutic Approach to HEV Infection	<i>Lubna Kamani (Liaquat National Hospital, Pakistan)</i>
10:15-10:30	Pathogenesis and Management of Non-Hepatotropic Viruses	<i>Ju-Yeon Cho (Chosun Univ., Korea)</i>
10:30-10:50	Coffee Break	
10:50-11:50	Symposium 2-5. Metabolic Disease and Viral Hepatitis	<i>Jose D. Sollano (The Univ. of Santo Tomas, Philippines)</i> <i>Oh Sang Kwon (Gachon Univ., Korea)</i> <i>Sang Hoon Park (Hallym Univ., Korea)</i>
10:50-11:05	Role of Metabolic Risk Factors in the Outcome of Viral Hepatitis	<i>Lai Wei (Tsinghua Univ., China)</i>
11:05-11:20	Effects of Alcohol Drinking on the Prognosis of Patients with Viral Hepatitis	<i>Won Kim (Seoul National Univ., Korea)</i>
11:20-11:35	MAFLD in Chronic Hepatitis B: Friend or Foe?	<i>Lung-Yi Mak (The Univ. of Hong Kong, Hong Kong)</i>
11:35-11:50	Management Strategies for Viral Hepatitis with Concurrent MAFLD	<i>Hye Won Lee (Yonsei Univ., Korea)</i>
11:50-12:50	Luncheon Symposium 5  YUHAN	

14:40-16:00	Symposium 2-6. Prevention and Surveillance of Viral Hepatitis-Associated HCC	<i>Shuichiro Shiina (Juntendo Univ., Japan)</i> <i>Joong-Won Park (National Cancer Center, Korea)</i> <i>Jong Young Choi (The Catholic Univ. of Korea, Korea)</i>
14:40-15:00	Anti-HBV Therapy to Prevent HBV-Associated HCC <i>Tetsuya Hosaka (Toranomon Hospital, Japan)</i>	
15:00-15:20	Anti-HCV Therapy to Prevent HCV-Associated HCC <i>Do Young Kim (Yonsei Univ., Korea)</i>	
15:20-15:40	Non-Viral Managements to Prevent HCC <i>Dong Hyun Sinn (Sungkyunkwan Univ., Korea)</i>	
15:40-16:00	Risk-Stratified Surveillance for Hepatitis Virus-Associated HCC <i>Shuichiro Shiina (Juntendo Univ., Japan)</i>	
16:00-16:20	Coffee Break	
16:20-17:40	Symposium 2-8. AI and Machine Learning for Liver Disease Management	<i>Il Han Song (Dankook Univ., Korea)</i> <i>Moon Seok Choi (Sungkyunkwan Univ., Korea)</i>
16:20-16:40	Developing AI Model for Predicting HCC <i>Hwi Young Kim (Ewha Womans Univ., Korea)</i>	
16:40-17:00	Radiomics and Deep Learning for Chronic Liver Disease <i>Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand)</i>	
17:00-17:20	Harnessing Knowledge and Experimental Data Using AI Drug Discovery Technology <i>Hanjo Kim (Standigm, Korea)</i>	
17:20-17:40	Deep Learning-Based Prediction of Biomarkers Using Liver Cancer Histopathological Images <i>Sung Hak Lee (The Catholic Univ. of Korea, Korea)</i>	

09:30-10:30	SIG 2. cccDNA and HBV Integration: Stumbling Blocks for HBV Cure	<i>Kyun-Hwan Kim (Sungkyunkwan Univ., Korea)</i> <i>Byung-Cheol Song (Jeju Univ., Korea)</i>
09:30-09:50	HBV cccDNA: Mechanism of Its Formation and Therapeutic Targets <i>Kyun-Hwan Kim (Sungkyunkwan Univ., Korea)</i>	
09:50-10:10	HBV Integration and Liver Cancer <i>Thomas Tu (Westmead Institute for Medical Research, Australia)</i>	
10:10-10:30	Genome Editing for cccDNA and Integrated HBV <i>Jae Young Lee (ToolGen, Korea)</i>	
10:30-10:50	Coffee Break	

10:50-11:50	SIG 3. Immunopathogenesis of Viral Hepatitis	<i>Jeong Heo (Pusan National Univ., Korea)</i> <i>Eui-Cheol Shin (KAIST, Korea)</i>
10:50-11:05	Type I and Type III Interferon Responses in Hepatitis Virus Infection <i>Pil Soo Sung (The Catholic Univ. of Korea, Korea)</i>	
11:05-11:20	T-Cell Responses and Immunopathogenesis of Chronic Hepatitis B <i>Yuri Cho (National Cancer Center, Korea)</i>	
11:20-11:35	Characteristics of B-Cells in HBV-Associated Chronic Liver Disease <i>Ji Eun Oh (KAIST, Korea)</i>	
11:35-11:50	Chronic Hepatitis and Liver Fibrosis in Humans <i>Hideki Ueno (Kyoto Univ., Japan)</i>	
11:50-12:50	Luncheon Symposium 6  DAEWOONG	

* 전공의 및 전임의를 위한 특별세션 "Hepatology Associate - Education Forum"을 수강하실 경우 추가평점이 주어집니다.
(본 평점을 위해서는 해당 강의실 앞에 설치된 QR 스캐너를 통해 명찰을 꼭 인식시켜 주시기 바랍니다.)

13:20-14:20	Hepatology Associates - Education Forum 1. Approach to Various Chronic Liver Disease 	<i>Tae Hun Kim (Ewha Womans Univ., Korea)</i> <i>Jung Woo Shin (Univ. of Ulsan, Korea)</i>
13:20-13:35	Treatment of Chronic Hepatitis B: When and Whom? <i>Jae Yoon Jeong (National Medical Center, Korea)</i>	
13:35-13:50	Diagnosis and Management of Hepatitis C Virus Infection <i>Woo Sun Rou (Chungnam National Univ., Korea)</i>	
13:50-14:05	Diagnosis and Management of Autoimmune Hepatitis <i>Young Chang (Soonchunhyang Univ., Korea)</i>	
14:05-14:20	Surveillance and Diagnosis of HCC <i>Han Ah Lee (Ewha Womans Univ., Korea)</i>	
14:20-14:40	Coffee Break	

*	Hepatology Associates - Education Forum 2. Metabolism, Alcohol, and Toxicity K	<i>Byung Seok Lee (Chungnam National Univ., Korea) Gab Jin Cheon (Univ. of Ulsan, Korea)</i>
14:40-16:00	Epidemiology, Natural History, and Risk Stratification of NAFLD <i>Yang-Hyun Baek (Dong-A Univ., Korea)</i>	
15:00-15:20	Lifestyle Intervention and Available Medications in NAFLD Treatment <i>Se Young Jang (Kyungpook National Univ., Korea)</i>	
15:20-15:40	Management of Severe Alcoholic Hepatitis <i>Tae Suk Kim (Kangwon National Univ., Korea)</i>	
15:40-16:00	Updated Guideline on Drug-Induced Liver Injury <i>Nae-Yun Heo (Inje Univ., Korea)</i>	
16:00-16:20	Coffee Break	

*	Hepatology Associates - Education Forum 3. Cirrhosis and Complications: Case-Based Learning K	<i>Chang Hyeong Lee (Daegu Catholic Univ. Korea) Young Seok Kim (Soonchunhyang Univ., Korea)</i>
16:20-17:40	Diagnosis and Management of Ascites and Related Complications <i>Chang Hun Lee (Jeonbuk National Univ., Korea)</i>	
16:40-17:00	Diagnosis and Management of Acute Variceal Bleeding <i>Seong Hee Kang (Korea Univ., Korea)</i>	
17:00-17:20	When Is the Appropriate Time for Liver Transplantation? <i>Kwang Il Seo (Kosin Univ., Korea)</i>	
17:20-17:40	Treatment Strategy Based on HCC Stage <i>Jung Hwan Yu (Inha Univ., Korea)</i>	

K Session in Korean

Scientific Program

Room 3-1 (2F)

September 22, 2023

Light Breakfast Provided

07:30-08:20 **Early Morning Workshop 1. Emerging Risk Factors of HCC in Chronic Hepatitis B**

*Diana A. Payawal
(Fatima Medical Univ., Philippines)*

07:30-07:42 Impact of Metabolic Factors on the Risk of HBV-Related HCC
Yun Bin Lee (Seoul National Univ., Korea)

07:42-07:54 Have Risk Factors for HCC Changed over the Decades?
Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand)

07:54-08:20 Discussion
Discussants: Yun Bin Lee (Seoul National Univ., Korea), Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand), Kang Mo Kim (Univ. of Ulsan, Korea), Tai-Chung Tseng (National Taiwan Univ., Taiwan)

Room 3-2 (2F)

September 22, 2023

Light Breakfast Provided

07:30-08:20 **Early Morning Workshop 2. Real-Life Experiences in HCV Management**

Ming-Lung Yu (National Sun Yat-sen Univ., Taiwan)

07:30-07:42 Are Metabolic Derangements Corrected after Cure of HCV?
Eun Ju Cho (Seoul National Univ., Korea)

07:42-07:54 Effects of DAA Treatment on Extrahepatic Manifestations in HCV Infection
Hyun Phil Shin (Kyung Hee Univ., Korea)

07:54-08:20 Discussion
Discussants: Eun Ju Cho (Seoul National Univ., Korea), Hyun Phil Shin (Kyung Hee Univ., Korea), Tetsuya Hosaka (Toranomon Hospital, Japan), Geum-Youn Gwak (Sungkyunkwan Univ., Korea)



Program at a Glance

DAY 3 September 23, 2023

TIME	ROOM 1 (1F)	ROOM 2 (2F)	ROOM 3-1 (2F)	ROOM 3-2 (2F)	ROOM 4 (3F)
07:00					
08:00			EMW 3	EMW 4	
09:00	Symposium 3-1	Symposium 3-2		Free Paper Presentation 1	Poster Viewing
10:00	Keynote Lecture 3			Free Paper Presentation 2	
Coffee Break					
11:00	State-of-the-Art Lecture 3				Poster Viewing
	Debrief Session				
12:00	Closing & Award Ceremony				
13:00					
14:00					
15:00					

08:30-09:30	Symposium 3-1. Occult Hepatitis Virus Infection and Post-Cure Virologic Failure	<i>Patrick Kennedy (Queen Mary Univ. of London, UK) Kwan Sik Lee (CHA Univ., Korea)</i>
08:30-08:45	A Twist to a Cure of HCV Infection: Occult HCV Infection	<i>Atsumasa Komori (Nagasaki Univ., Japan)</i>
08:45-09:00	Re-Infection of HCV Post-SVR	<i>Ki Tae Yoon (Pusan National Univ., Korea)</i>
09:00-09:15	Occult HBV Infection: The Fate and Clinical Implications	<i>Man-Fung Yuen (The Univ. of Hong Kong, Hong Kong)</i>
09:15-09:30	Threat: HBV Reactivation after Resolved Hepatitis B	<i>Su Jong Yu (Seoul National Univ., Korea)</i>
09:30-10:30	Keynote Lecture 3. What Happens to the Liver after a Cure of Viral Hepatitis?	<i>Man-Fung Yuen (The Univ. of Hong Kong, Hong Kong) Marc G. Ghany (NIH, USA)</i>
09:30-09:50	cccDNA and HBV Functional Cure Is CccDNA the Chicken or the Egg?	<i>Robert G. Gish (Hepatitis B Foundation, USA)</i>
09:50-10:10	HBV Integration as a Novel Biomarker and Barrier to a Cure for HBV Infection	<i>Patrick Kennedy (Queen Mary Univ. of London, UK)</i>
10:10-10:30	Immune Reconstitution after HCV Clearance with Direct Antiviral Agents	<i>Tatsuya Kanto (National Center for Global Health and Medicine, Japan)</i>
10:30-10:50	Coffee Break	
10:50-11:20	State-of-the-Art Lecture 3	<i>Shiv Kumar Sarin (Institute of Liver & Biliary Sciences, India)</i>
10:50-11:20	A Roadmap to Eliminating Viral Hepatitis	<i>Norah Terrault (Univ. of Southern California, USA)</i>
11:20-11:50	Debrief Session	<i>Jeong Won Jang (The Catholic Univ. of Korea, Korea)</i>
11:20-11:30	Viral Hepatitis Debrief	<i>Hye Won Lee (Yonsei Univ., Korea)</i>
11:30-11:40	Non-Viral Liver Disease Debrief	<i>Pil Soo Sung (The Catholic Univ. of Korea, Korea)</i>
11:40-11:50	Wrap-Up	<i>Jeong Won Jang (The Catholic Univ. of Korea, Korea)</i>
11:50-12:20	Closing & Award Ceremony	

Scientific Program

ROOM 2 (2F)

September 23, 2023

08:30-09:30 **Symposium 3-2. Precision Medicine for the Cure of Viral Liver Disease** *W. Ray Kim (Stanford Univ., USA)
Joon Hyeok Lee (Sungkyunkwan Univ., Korea)*

08:30-08:45 Personalized Management of Viral Hepatitis of the Present and the Future
Maria Buti Ferret (Hospital Universitario Valle Hebron, Spain)

08:45-09:00 Risk Stratification for HCC in Chronic Hepatitis B: A Promise for Precision Medicine
Won Sohn (Sungkyunkwan Univ., Korea)

09:00-09:15 Host and Genetic Factors for Precision Medicine towards a Cure of Viral Hepatitis
Kazuaki Chayama (Hiroshima Univ., Japan)

09:15-09:30 Biomarker Discovery and Application for Liver Disease in the Era of Precision Medicine
Sun Young Yim (Korea Univ., Korea)

Room 3-1 (2F)

September 23, 2023

Light Breakfast Provided

07:30-08:20 **Early Morning Workshop 3. Fibrosis Regression after Antiviral Therapy in Patients with Chronic Viral Hepatitis** *Atsumasa Komori (Nagasaki Univ., Japan)*

07:30-07:42 Fibrosis Regression after HCV Treatment and Its Clinical Significance
Jeong-Ju Yoo (Soonchunhyang Univ., Korea)

07:42-07:54 Clinical Implication of On-Therapy Fibrosis Regression in Chronic Hepatitis B
Mi Na Kim (Yonsei Univ., Korea)

07:54-08:20 Discussion
Discussants: Jeong-Ju Yoo (Soonchunhyang Univ., Korea), Mi Na Kim (Yonsei Univ., Korea), Sung Jae Park (Inje Univ., Korea), Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand)

Room 3-2 (2F)

September 23, 2023

Light Breakfast Provided

07:30-08:20 **Early Morning Workshop 4. Screening and Prognosis of HDV Infection with Case Discussion** *Jose D. Sollano (The Univ. of Santo Tomas, Philippines)*

07:30-07:37 Threat: Who Should Be Screened for HDV Infection? - Case Presentation
Hee Yeon Kim (The Catholic Univ. of Korea, Korea)

07:37-07:45 Who Should Be Screened for HDV Infection?
Jae Hyun Yoon (Chonnam National Univ., Korea)

07:45-07:57 Prognosis of HDV: Risk Factors and Whom to Treat
Lubna Kamani (Liaquat National Hospital, Pakistan)

07:57-08:20 Discussion
Discussants: Hee Yeon Kim (The Catholic Univ. of Korea, Korea), Jae Hyun Yoon (Chonnam National Univ., Korea), Lubna Kamani (Liaquat National Hospital, Pakistan), Ji Hoon Kim (Korea Univ., Korea)

LUNCHEON INDUSTRY SYMPOSIA

DAY 1 Thursday, September 21, 2023

Room 1	Advances in HCV Care <i>Do Young Kim (Yonsei Univ., Korea)</i>
abbvie	HCV Treatments of Today: Short, Simple, Safe, and Effective! <i>Tarik Asselah (Hepatology at Hôpital Beaujon, France)</i>
	HCV Treatments of Today: A Step Closer to Global HCV Elimination Goals <i>Tarik Asselah (Hepatology at Hôpital Beaujon, France)</i>
	HCV Treatments of Today: The Korean Experience <i>Su Jong Yu (Seoul National Univ., Korea)</i>
Room 2	Tecentriq + Avastin: Exploring the Real World Experience <i>Yoon Jun Kim (Seoul National Univ., Korea)</i>
Roche	Study of IMbrave150 and RWD in Populations Including High-Risk Individuals <i>Jeong Heo (Pusan National Univ., Korea)</i>
Room 3	NAFLD Update and GODEX <i>Yong Kyun Cho (Sungkyunkwan Univ., Korea)</i>
CELLTRION PHARM CELLTRION	NAFLD Update and GODEX <i>Seung Up Kim (Yonsei Univ., Korea)</i>

DAY 2 Friday, September 22, 2023

Room 1	A Paradigm Shift in the Management of Chronic Hepatitis C <i>Sang Hoon Ahn (Yonsei Univ., Korea)</i>
GILEAD	Accelerating the Progress of HCV Elimination in Korea <i>Sang Hoon Ahn (Yonsei Univ., Korea)</i>
	Together We Can Achieve HCV Elimination through Simplification <i>Robert G. Gish (Hepatitis B Foundation, USA)</i>
Room 2	LDL-C Lowering Therapy <i>Jin-Wook Kim (Seoul National Univ., Korea)</i>
YUHAN	LDL-C Lowering Therapy: The Journey towards Elimination of Atherosclerosis <i>Cheol Hwan Lee (Univ. of Ulsan, Korea)</i>
Room 3	New Waves of GERD Treatment <i>Hyung Joon Kim (Chung-Ang Univ., Korea)</i>
DAEWOONG	New Waves of GERD Treatment: Fexuprazan <i>Gwang Ha Kim (Pusan National Univ., Korea)</i>

Free Paper Presentation

Room 3-2 (2F)

Saturday, September 23, 2023 [08:30-09:30]

 Young Investigator Award

1. Viral Liver Disease

So Young Kwon (Konkuk Univ., Korea), Jin-Woo Lee (Inha Univ., Korea)

08:30-08:40 [FP-01] Positive Rates of Autoantibodies in Chronic Hepatitis C Patients before and after DAA Therapy: A Prospective, Multicenter Study in South Korea
Su Hyun Choi (Seoul National University, Korea)

 08:40-08:50 [FP-02] Prediction of Long-Term HBsAg Seroclearance after Entecavir Cessation in Chinese Hepatitis B Patients with the Novel Alanine-Aminotransferase to Quantitative-HBsAg Ratio
Rex Wan-Hin Hui (The University of Hong Kong, Hong Kong)

 08:50-09:00 [FP-03] Metabolic Effects of Antiviral Treatments in Patients with Chronic Hepatitis B
Hyunjae Shin (Seoul National University, Korea)

09:00-09:10 [FP-04] CAMP-B Score Predicts the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B after HBsAg Seroclearance
Jonggi Choi (University of Ulsan, Korea)

09:10-09:20 [FP-05] Strategy on Hepatitis C Virus Elimination Focused on Economic Evaluation of Mass Screening in Korea
Hwa Young Choi (National Cancer Center, Korea)

09:20-09:30 [FP-06] Antiviral Therapy and Risk for Hepatocellular Carcinoma after Hepatitis B Surface Antigen Seroclearance
Han Ah Lee (Ewha Womans University, Korea)

Saturday, September 23, 2023 [09:30-10:30]

2. Non-Viral Liver Disease

Yong Kyun Cho (Sungkyunkwan Univ., Korea), Hyung Joon Kim (Chung-Ang Univ., Korea)

09:30-09:40 [FP-07] Analysis of Immune-Related Adverse Events and Time-to-Treatment Discontinuation of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study
Heechul Nam (The Catholic University of Korea, Korea)

 09:40-09:50 [FP-08] Long-Term Outcome of Wilson's Disease: Single Center Analysis of 361 Asian Patients
Hyojin Nam (University of Ulsan, Korea)

09:50-10:00 [FP-09] Enhancing Early Hepatitis Diagnosis: Optimizing Decision Trees with Genetic Algorithms
Rifaldy Fajar (Karlstad University, Sweden)

10:00-10:10 [FP-10] Bifidobacterium Breve and Longum Attenuate Western Diet Induced Non-Alcoholic Fatty Liver Disease
Sang Jun Yoon (Hallym University, Korea)

 10:10-10:20 [FP-11] Landscape of T-Cell Exhaustion Heterogeneity in Hepatocellular Carcinoma: Insights from Integrating Whole Exome, Transcriptomes, and Single-Cell Sequencing
Soon Kyu Lee (The Catholic University of Korea, Korea)

10:20-10:30 [FP-12] Analysis of Discordance between Transient Elastography and Liver Biopsy for Assessing Liver Fibrosis in Patients with Chronic Viral Hepatitis
Seong Hee Kang (Korea University, Korea)

Oral Poster Presentation

Lobby (3F)

Thursday, September 21, 2023 [10:50-11:50]

 Young Investigator Award

1. NAFLD and Alcohol-Related Liver Disease

Won Hyeok Choe (Konkuk Univ., Korea)
Byoung Kuk Jang (Keimyung Univ., Korea)

- 10:50-11:00 [OP-01] Solid Lipid Nanoparticle Ganodric Acid Ameliorates the High Fat Induced Non-Alcoholic Fatty Liver Disease via Alteration Gut Microbiota and PI3K/AKT/mTOR Signaling Pathway
Vikas Kumar (Sam Higginbottom University, India)
- 11:00-11:10 [OP-02] Inhibition of CHIT1 as a Potential Therapeutic Approach for Liver Fibrosis
Sung Woo Cho (The Catholic University, Korea)
-  11:10-11:20 [OP-03] Prevalence and Predictors of Multidrug Resistant Bacteremia in Liver Cirrhosis
Aryoung Kim (Sungkyunkwan University, Korea)
- 11:20-11:30 [OP-04] Dynamic Changes of Metabolic Dysfunction-Associated Fatty Liver Disease Status Were Associated with the Liver-Related Long-Term Outcomes: A Nationwide Cohort Study
Yun Mi Ko (Seoul National University, Korea)
-  11:30-11:40 [OP-05] Polyethylene Glycol Reduces Hangover Symptoms with Protection of Liver and Intestine against Alcohol Consumption
Tom Ryu (Soonchunhyang University, Korea)
-  11:40-11:50 [OP-06] Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
Sang Yi Moon (Dong-A University, Korea)

Thursday, September 21, 2023 [13:20-14:20]

2. Liver Cirrhosis and Others

Soon Woo Nam (The Catholic Univ. of Korea, Korea)
Su Cheol Park (Korea Cancer Center Hospital, Korea)

- 13:20-13:30 [OP-07] Prognosis after Sustained Virologic Response of Chronic Hepatitis C Patients Treated with Sofosbuvir Based Treatment: 5 Years Follow Up Data of Multicenter Prospective Observational Study
Jeong Han Kim (Konkuk University, Korea)
-  13:30-13:40 [OP-08] Increased Risk of Osteoporotic Fractures in Patients with Primary Biliary Cholangitis
Jihye Lim (The Catholic University of Korea, Korea)
-  13:40-13:50 [OP-09] Azathioprine on Risk of Extrahepatic Malignancy in Patients with Autoimmune Hepatitis: A Nationwide Claims Study in South Korea
Sung Hwan Yoo (Yonsei University, Korea)
- 13:50-14:00 [OP-10] Mathematical Modeling to Evaluate Feasibility and Strategies for Controlling Hepatitis B Virus Infection in Indonesia
Prihantini (Bandung Institute of Technology, Indonesia)
- 14:00-14:10 [OP-11] Intrahepatic IgA Complex Induces Polarization of CAFs into Matrix CAFs and Upregulates PD-L1 Expression in the Tumor Microenvironment of HCC
Jong Geun Park (The Catholic University of Korea, Korea)
- 14:10-14:20 [OP-12] Role of Portosystemic Shunt and Portal Vein Stent in Managing Portal Hypertension due to Hematological Malignancies
Ji Hoon Kim (The Catholic University of Korea, Korea)

Oral Poster Presentation

Lobby (3F)



Friday, September 22, 2023 [08:30-09:30]



Young Investigator Award

3. Viral Hepatitis



Hyung Joon Yim (Korea Univ., Korea), Byung Seok Kim (Daegu Catholic Univ., Korea)

- 08:30-08:40 [OP-13] Comparison of the Effects of Switching from Tenofovir Disoproxil Fumarate to Either Entecavir or Tenofovir Alafenamide on Kidney Function in Chronic Hepatitis B: Retrospective Cohort Study
Eunjee Lim (Seoul National University, Korea)
- 08:40-08:50 [OP-14] Prevalence of Hepatitis B Virus Core Antibody in Indian Blood Donors: Implications for Safe Transfusion
Ashok Kumar Sah (Galgotia University, India)
- 08:50-09:00 [OP-15] In Silico and in Vitro Anti-Hepatitis B Virus Activity of Bioassay-Guided Compound Quercetin and Myricetin-3-O-Rhamnoside from Pistacia Lentiscus
Deepika Singh (SHUATS, India)
- 09:00-09:10 [OP-16] The Effectiveness of Ultrasonography-Based Surveillance of Hepatocellular Carcinoma according to the Ultrasound LI-RADS Visualization Score in Chronic Hepatitis B Patients
Yun Mi Ko (Seoul National University, Korea)
-  09:10-09:20 [OP-17] Effectiveness of Phyllanthus Urinaria Leaves Combined with Tenofovir in Treatment of Chronic Hepatitis B
Ha Linh (103 Cam Khe Clinic, Vietnam)
-  09:20-09:30 [OP-18] Association between Baseline Viral Load and On-Treatment Risk of Hepatocellular Carcinoma in Chronic Hepatitis B
Won-Mook Choi (University of Ulsan, Korea)

Friday, September 22, 2023 [09:30-10:30]

4. HCC

Soo Young Park (Kyungpook National Univ., Korea), Yeon Seok Seo (Korea Univ., Korea)

-  09:30-09:40 [OP-19] Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
Jonggi Choi (University of Ulsan, Korea)
- 09:40-09:50 [OP-20] Association of Proton Pump Inhibitors and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Korean Nationwide Cohort Study
Young Youn Cho (Chung-Ang University, Korea)
-  09:50-10:00 [OP-21] Effects of Hepatocellular Carcinoma Screening Test on Survival in the Elderly Patients
Aryoung Kim (Sungkyunkwan University, Korea)
- 10:00-10:10 [OP-22] Clinico-Pathological Characterization of hTERT-Telomere Abnormalities in Hepatocellular Carcinoma
Jung Eun Jang (The Catholic University of Korea, Korea)
- 10:10-10:20 [OP-23] Artificial Intelligence Model to Predict De Novo Hepatocellular Carcinoma after 5 Years of Antiviral Therapy
Yeonjung Ha (CHA University, Korea)
- 10:20-10:30 [OP-24] Modified Albumin-Bilirubin Grade after Curative Treatment: Risk Prediction of Late Intrahepatic Recurrence of Hepatocellular Carcinoma
Jeong Il Yu (Sungkyunkwan University, Korea)

Alcoholic Liver Disease

PE-01	Characteristics of Microbiome-Derived Metabolomics according to the Progression of Alcoholic Liver Disease <i>Raja Ganesan (Hallym University, Korea)</i>
PE-02	Gut-Microbiota Prompted Activation of Natural Killer Cell on Alcoholic Liver Disease <i>Jung A Eom (Institute for Liver and Digestive Disease, Korea)</i>
PE-03	Dose-Response Relationship between Alcohol Consumption and Incidence of Liver Disease: A Nationwide Cohort Study <i>Sang Yi Moon (Dong-A University, Korea)</i>

Hepatitis A/E: Basic and Translational Research

PE-04	A Newly Developed in-House Double Antigen Sandwich ELISA for Detection of Anti-HEV IgG among Pregnant Women in Cambodia <i>Mirzaev Ulugbek Khudayberdievich (Hiroshima University, Japan)</i>
PE-05	The Seroprevalence of Hepatitis E Virus in the Ethnic Minorities of Ha Giang Province, Vietnam <i>Egeniia Lichnaia (Saint-Petersburg Pasteur Institute, Russia)</i>

Hepatitis A/E: Clinical Aspects

PE-06	A Silent Outbreak of Hepatitis E Virus Infection or False Positive Reaction of Anti-HEV IgM after COVID-19 Vaccination?: Epidemiological Investigation of an Outbreak in a Korean Factory Complex in 2022 <i>Gwang Hyeon Choi (Seoul National University, Korea)</i>
PE-07	Continuous Renal Replacement Therapy in Pediatric Patients with Hepatitis A Virus Associated Acute Liver Failure with Advanced Hepatic Encephalopathy- Effect on Survival <i>Arjun Maria (Sir Ganga Ram Hospital, India)</i>
PE-08	Risk Factors for Development of Cirrhosis in Chronic Viral Hepatitis B Patients Who Had Persistent Viral Suppression with Antiviral Therapy <i>Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand)</i>
PE-09	Hepatitis B Virus Screening Rate in Cancer Patients before Receiving Chemotherapy: A Systematic Review and Meta-Analysis <i>Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand)</i>

Hepatitis B: Basic and Translational Research

PE-10	The Prevalence of Genotypes and Subtypes of HBV in Kazakhstan <i>Balzhhan Abzhaparova (The A.Syzganov's National Scientific Center, Kazakhstan)</i>
PE-11	Risk Factors for Hepatitis B Incidence in Pregnant Women in Indonesia: A Literature Review <i>Rinita Istiqomah (Yogyakarta State University, Indonesia)</i>
PE-12	The Role of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level in Stratifying Hepatocellular Carcinoma (HCC) Risks in Chronic Hepatitis B (CHB) Patients with Oral Antiviral Therapy <i>Roland Helmizar (Baiturrahmah University, Indonesia)</i>
PE-13	Superior Performance of Intrahepatic HBV Markers to Circulating Markers in Predicting Sustained Inactive Carriers in Chronically Infected Patients <i>Hye Seon Kim (The Catholic University of Korea, Korea)</i>
PE-14	Reduced Intrahepatic Levels and Transcriptional Activity of cccDNA Contribute to Lower Viremia in HBeAg-Negative Chronic Hepatitis B Patients <i>Hye Seon Kim (The Catholic University of Korea, Korea)</i>
PE-15	Correlation between Platelet-Lymphocyte Ratio and Degree of Liver Fibrosis in Chronic Hepatitis B Patients in Indonesia <i>Putri Ayu (Andalas University, Indonesia)</i>
PE-16	Association of Hepatitis B Core Antibody with Treatment Response of Chronic Hepatitis B Patients <i>Putri Ayu (Andalas University, Indonesia)</i>
PE-17	Attenuation of Concanavalin A-Induced Autoimmune Hepatitis by Hesperidin in Mice via Gut Microbiota & Nrf2/NF-Kb Pathways Signalling Pathways <i>Deepika Singh (SHUATS, India)</i>
PE-18	Evaluation and Comparative Study of Machine Learning-Based Models to Determine the Seropositivity of Hepatitis B Virus (HBV) <i>Manvendra Singh (HMFA-MIET, India)</i>

Hepatitis B: Clinical Aspects

PE-19	Epidemiology and Treatment Status of Hepatitis B Patients in a Korea HBV Cohort Study: A Prospective Multi-Center Cohort Study <i>Oeuk Jeong (Korea National Institute of Health, Korea)</i>
PE-20	Trends of Liver Function Tests among Residents Undergoing Health Screening in Beijing, 2009-2022 <i>Yifan Geng (Hainan Medical University, China)</i>
PE-21	Predictors of Hepatitis Flare and Initiation of Antiviral Therapy in Nucleos(T)ide-Chronic Hepatitis B in Grey-Zone <i>Yunjeong Lee (Seoul National University, Korea)</i>

Hepatitis B: Clinical Aspects

PE-22	Baseline and Reduction at 1 Year of Hepatitis B Surface Antigen Level Predicts Functional Cure and Low HBsAg Titer: A Long-Term Kinetics of Hepatitis B Surface Antigen according to Disease Status <i>Soon Kyu Lee (The Catholic University of Korea, Korea)</i>
PE-23	Long-Term Outcomes of HBeAg-Positive Grey-Zone Patients <i>Dongwoo Cho (The Catholic University of Korea, Korea)</i>
PE-24	Discontinuation of Antiviral Therapy even after 12 Month-Maintenance following Hematopoietic Stem Cell Transplantation Is Associated with the HBV Reactivation in HBsAg-Positive Subjects <i>Ji Won Han (The Catholic University of Korea, Korea)</i>
PE-25	Aspirin Use and Risk of Hepatocellular Carcinoma and Gastrointestinal Bleeding in Patients with HBV-Related Cirrhosis <i>Mi Na Kim (Yonsei University, Korea)</i>
PE-26	Clinical Significance of Mac-2 Binding Protein Glycosylation Isomer in Korean Patients with Chronic Hepatitis B: Comparative Study of Non-Invasive Modality for Diagnosis of Liver Fibrosis <i>Jae-Sung Yoo (The Catholic University of Korea, Korea)</i>
PE-27	Clinical Usefulness of Serum ELF Levels on Diagnosing Liver Cirrhosis in Patients with Chronic Hepatitis B <i>Jun Yeb Nam (Kosin University, Korea)</i>
PE-28	Hepatitis B Surface Antigen Seroclearance Rate in Cheorwon Area, Korea <i>Jae-Jun Shim (Cheorwon Hospital, Korea)</i>
PE-29	A Mediation Analysis of Dynamic Process of Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients with Antiviral Treatment <i>Minjoo Cho (University of Ulsan, Korea)</i>
PE-30	Impact of Metabolic-Associated Fatty Liver Disease on Treatment Response in Nucleos(t)ide Analogue-Treated Chronic Hepatitis B <i>Juseok Lee (Daegu Catholic University, Korea)</i>
PE-31	Efficacy of Antiviral Prophylaxis up to 6 or 12 Months after Completion of Rituximab in Resolved Hepatitis B: A Multicenter Randomized Controlled Trial <i>Heejoon Jang (Seoul National University, Korea)</i>
PE-32	Entecavir versus Tenofovir on the Recurrence of Hepatitis B Virus Related Hepatocellular Carcinoma after Liver Transplantation: A Korean Nation-Wide Study <i>Deok-Gie Kim (Yonsei University, Korea)</i>
PE-33	Treated Chronic Hepatitis B Is a Good Prognostic Factor of Diffuse Large B-Cell Lymphoma <i>Jeayeon Park (Seoul National University, Korea)</i>
PE-34	COVID-19 Vaccination Alters NK Cell Dynamics and Transiently Reduces HBsAg Titers among Patients with Chronic Hepatitis B <i>Hyunjae Shin (Seoul National University, Korea)</i>
PE-35	Effect of Age on HBsAg Clearance in Children with HBeAg-Positive Chronic Hepatitis B Undergoing Antiviral Therapy <i>Byung-Ho Choe (Kyungpook National University, Korea)</i>

Hepatitis B: Current Treatment

PE-36	Bibliometric Study on Antiviral Agents against Hepatitis B Virus in Scopus Database (2018-2023) <i>Rian Ka Praja (Universitas Palangka Raya, Indonesia)</i>
PE-37	Efficacy Comparison of High Genetic Barrier Nucleos(t)ide Analogues in Treatment-Naïve Chronic Hepatitis B Patients: A Network Meta-Analysis <i>Jaejun Lee (The Catholic University of Korea, Korea)</i>
PE-38	Severe Extrahepatic Manifestation Involving Mucosa and Skin in Chronic Hepatitis B Infection: A Case Report <i>Shin Young Park (Chonnam National University, Korea)</i>
PE-39	The Change of HBCrAg in Patients with Hepatitis B before and after Treatment with Tenofovir Disoproxil Fumarate <i>Le Hien (Thai Nguyen University, Vietnam)</i>
PE-40	State of Fibrosis Following NA Therapy in Patient with Chronic Hepatitis B Virus Infection <i>Chinzorig (MASLD, Mongolia)</i>
PE-41	Effects of Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide on Risk of Osteoporotic Fracture in Patients with Chronic Hepatitis B: A Nationwide Claims Study <i>Eunju Kim (Chung-Ang University, Korea)</i>
PE-42	Comparable Risk of Cardiovascular Events in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide <i>Hyeyeon Hong (University of Ulsan, Korea)</i>
PE-43	Comparable Risk of Renal Dysfunction between Entecavir and Tenofovir Alafenamide in Patients with Chronic Hepatitis B <i>Yeojin Lee (University of Ulsan, Korea)</i>
PE-44	A 7th-Year Interim Analysis of Prospective and Longitudinal Korean Chronic Hepatitis B Cohort <i>Jae Seung Lee (Yonsei University, Korea)</i>
PE-45	How Effective Is the Method of Treating Hepatitis B with Temulawak? <i>Andi Nursanti (Andini Persada College, Indonesia)</i>

Hepatitis B: Diagnostics and Biomarkers

PE-46	The Correlation between Interleukin-6 and the Progression of Chronic Hepatitis B <i>Mohamed Shafi Bin Mahboob Ali (Advanced Medical and Dental Institute, Malaysia)</i>
PE-47	Performance of the Elecsys HBeAg Quant Assay against a Seroconversion Panel <i>Christian Voitenleitner (Roche Diagnostics International Ltd, Switzerland)</i>
PE-48	Comorbidities in Indian Hemodialysis Patients with Chronic Hepatitis B and Hepatitis C <i>Ravi Kumar (Onco Biomedical and Research Services, India)</i>

Hepatitis B: Diagnostics and Biomarkers

PE-49	Diagnostic Efficacy of Serum Asialo α 1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in CHB: A Prospective Cohort Study <i>Eunho Choi (Korea University, Korea)</i>
PE-50	Development of the Artificial HBV cccDNA System for Drug Screening <i>Yongwook Choi (Korea National Institute of Health, Korea)</i>

Hepatitis B: New Therapies and Trials

PE-51	Clinical and Virological Outcomes of Tenofovir Alafenamide Treatment in Patients with Hepatitis B Virus Infection <i>Tuvshinbayar Narangerel (State Second Central Hospital, Mongolia)</i>
PE-52	Evaluation of Sequential Therapy Peg-Interferon and Nucleos(t)ide Analogue Compared to Monotherapy in Patients with Chronic Hepatitis B <i>Roland Helmizar (Baiturrahmah University, Indonesia)</i>
PE-53	Non-Viral Gene Delivery Systems: Harnessing Nanotechnology for Therapeutic Applications in Hepatitis-B Infection <i>Avinash Kumar (Galgotias University, India)</i>
PE-54	Study of Phytocompounds Targeting the Protein of Hepatitis B Virus: An Insilico Analysis <i>Dhananjay Yadav (Yeungnam University, Korea)</i>

Hepatitis C: Basic and Translational Research

PE-55	Changes of Adiponectin-Leptin Ratio in Chronic Hepatitis C Patients before and after DAA Therapy: A Prospective, Multicenter Study in Korea <i>Jung Hoon Yoo (Seoul National University, Korea)</i>
PE-56	Implementation of a Community-Based Integrated Viral Hepatitis Prevention, Testing and Treatment Model for People Who Inject Drugs in Yangon, Myanmar <i>Mon Mon Su Naing (Burnet Institute, Myanmar)</i>
PE-57	Investigating Cross Transmission of Hepatitis C Virus among Rare and Limited Risk Groups in Japan <i>Zayar Phyoo (Hiroshima University, Japan)</i>
PE-58	Trends of the Prevalence of Hepatitis C Virus Infection by Region Using National Health Insurance Service from 2010 to 2022, Republic of Korea <i>Hwa Young Choi (National Cancer Center, Korea)</i>

Hepatitis C: Clinical Aspect: Therapy

PE-59	Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A Six-Year Multicenter Prospective Observational Study <i>Jeong Han Kim (Konkuk University, Korea)</i>
PE-60	Potential Antiviral siRNA Molecules for Silencing the 3'UTR of Hepatitis C Virus Genotype 1 <i>Rian Ka Praja (Universitas Palangka Raya, Indonesia)</i>
PE-61	Evaluation of Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure among Patients with Chronic Hepatitis C Infection <i>Haesuk Park (University of Florida, US)</i>
PE-62	Long-Term Durability of Direct-Acting Antiviral Therapy: Extended Virological Response Maintained for 12 Months in Hepatitis C Patients <i>Young Hyeon Ahn (Soonchunhyang University, Korea)</i>
PE-63	Real-Life Experience of Sofosbuvir-Based Therapy and Glecaprevir/Pibrentasvir for HCV Infected Korean Patients: A Multicenter Cohort Study <i>Seong Hee Kang (Korea University, Korea)</i>
PE-64	Treatment Efficacy and Safety Profile of Sofosbuvir and Velpastavir Based Treatment in South Korea: Multi-Institutional Prospective Study <i>Jae Hyun Yoon (Chonnam National University, Korea)</i>
PE-65	HCV Elimination and Prevention of Opioid Overdose Mortality through a Needle Exchange Program <i>Marianne Alanko Blomé (Skåne University Hospital, Sweden)</i>
PE-66	Metabolic Factors Influence the Efficacy of Direct Acting Antivirals against Chronic Hepatitis C on Liver Fibrosis <i>Tom Ryu (Soonchunhyang University, Korea)</i>
PE-67	Prognostic Factors of Post-Sustained Virological Response Outcome in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals <i>Won Sohn (Sungkyunkwan University, Korea)</i>
PE-68	Cascade of Care for Chronic Hepatitis C in South Korea <i>Sang Bong Ahn (Eulji University, Korea)</i>
PE-69	Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in Korea: A Retrospective Multicenter Study <i>Jae Yoon Jeong (National Medical Center, Korea)</i>
PE-70	The Risk of Hepatocellular Carcinoma Depending on Liver Cirrhosis in Patients with Chronic Hepatitis C: A National Cohort Study <i>Jong-In Chang (Chung-Ang University, Korea)</i>
PE-71	Impact of HCV Eradication on Symptoms of Extrahepatic Manifestations in Patients with Type 2 Diabetes Mellitus Treated with SOF/VEL <i>Ming-Lung Yu (National Sun Yat-sen University, Taiwan)</i>
PE-72	Hepatoprotective Effects of Temulawak Rhizome in the Study of Liver Disease in Hepatitis C <i>Andi Nursanti (Andini Persada College, Indonesia)</i>

Hepatitis C: Clinical Aspect Therapy

PE-73	Addition of Neutrophil-to-Lymphocyte Ratio to Pre-DAA FIB-4 to Predict De Novo Liver Complications in Hepatitis C <i>Chun-Ming Hong (National Taiwan University, Taiwan)</i>
-------	---

Hepatitis C: Clinical Aspects Non-Therapy

PE-74	Association between Hepatitis C, Autoimmune Hepatitis and Insulin Resistance <i>Javad Alizargar (NTUNHS, Iran)</i>
PE-75	Risk of Hepatitis C Virus Transmission through Acupuncture: A Systematic Review and Meta-Analysis <i>Hyun Yang (Korea University, Korea)</i>
PE-76	Interim Results of an Automated Electronic Medical Record-Based Alert System for The Micro-Elimination of Hepatitis C: A Single Center-Based Experience <i>Hee Yeon Kim (The Catholic University of Korea, Korea)</i>
PE-77	HCC Prediction Models Effectively Assess the Risk of HCC in Chronic Hepatitis C Patients without Advanced Fibrosis after Oral Antiviral Therapy: A Multicenter Study <i>Yu Rim Lee (Kyungpook National University, Korea)</i>
PE-78	An Artificial Intelligence Model for Prediction of Hepatocellular Carcinoma Development after Oral Antiviral Therapy in Patients with Chronic Hepatitis C <i>Yu Rim Lee (Kyungpook National University, Korea)</i>
PE-79	Screening, Confirmation, and Treatment Rate of Hepatitis C Virus Infection in Patients Undergoing Surgery in a Single Tertiary Academic Center <i>Jae Seung Lee (Yonsei University, Korea)</i>
PE-80	Rotary International and FIRE Projects <i>Munkhjargal Ayurzana (Rotary Club of Ulaanbaatar, Mongolia)</i>

Hepatitis D: Clinical Aspects Non-Therapy

PE-81	Relationship of HDV Infection to Increased Risk of Cirrhosis and HCC in Chronic Hepatitis B Patients <i>Derizal (Trisakti Institute of Tourism, Indonesia)</i>
-------	---

Hepatitis D: Current and New Therapies

PE-82	Efficacy of Pegylated Interferon-Alpha-2a in Chronic Hepatitis D Infected Patients <i>Derizal (Trisakti Institute of Tourism, Indonesia)</i>
-------	---

Liver Cancer: Basic and Translational Research

PE-83	Genetic Analysis of Three Dimensional Structure Like Human Liver, Evaluation Method of Hepatotoxicity and Conjugate Like Human Liver <i>Ramlah (Universitas Sulawesi Barat, Indonesia)</i>
PE-84	Antitumor Effects of Regorafenib on Hepatocellular Carcinoma and MicroRNA Expression <i>Kei Takuma (Kagawa University, Japan)</i>
PE-85	Evaluation of Alpha-Fetoprotein (AFP) Test in the Diagnosis of Hepatocellular Carcinoma <i>Le Hien (Thai Nguyen University, Vietnam)</i>
PE-86	Hesperidin Attenuates DEN Induced Liver Cancer in Rats via Inhibition of Activation of AMPK and Blocking of mTOR-Dependent Signaling Pathway <i>Deepika Singh (SHUATS, India)</i>
PE-87	Biofabrication and Characterization of Cationic Lipid Nanoparticles of Quercetin against DEN-Induced Liver Cancer in Rats <i>Niti Singh (MARLabs Innovation Pvt Ltd, India)</i>
PE-88	In Vitro and in Vivo Antitumor Effect of Biofabricated Silver Nanoparticles of Caffeic Acid against Hepatocarcinogenesis by Upregulation of Bax/Bcl2 <i>Ekta Yadav (Sam Higginbottom University, India)</i>
PE-89	Chemoprotective Effect of Crocetin-Dextrin Nano-Formulation against N-Diethylnitrosamine Induced Hepatocellular Carcinoma in Wistar Rats via Mitochondrial Apoptosis, Antioxidative, Anti-Inflammatory and PI3K/Akt/mTOR Signaling Pathways <i>Vikas Kumar (Sam Higginbottom University, India)</i>
PE-90	¹ H-NMR-Based Metabolomics Testing for Hepatocellular Carcinoma Potential of Umbelliferone on Diethyl Nitrosamine (DEN) Induced Metabolic Alteration <i>P Bhatt (Fermentis Biotech, India)</i>
PE-91	Solid Lipid Nanoparticle of Alpha-Mangostin Exerts Diethylnitrosamine Induced Hepatocellular Carcinoma via Alteration of PI3K/Akt Pathway <i>Kumar Patel (Chandra Shekhar Singh College, India)</i>
PE-92	Staging of Ovarian Cancer on the Basis of Liver Metastasis <i>Amar Ranjan (All India Institute of Medical Sciences, India)</i>
PE-93	Exosomal miRNA-720 Contributes to Hepatocellular Carcinoma Progression by Regulating StarD13 <i>Ji Min Kim (The Catholic University of Korea, Korea)</i>
PE-94	Inflammatory Cytokine Multiplex Analysis in Patients with Hepatocellular Carcinoma <i>Jae Mo Han (The Catholic University of Korea, Korea)</i>
PE-95	Depression Level among Elderly with Liver Function Decrease and Hypertension Status <i>Rosinta Hotmaida Pebrianti Purba (Learning-Up Institute, Indonesia)</i>

Liver Cancer: Basic and Translational Research

PE-96	The Management and Protocol of Liver Transplant (LT) in the Era of the COVID-19 Pandemic: Strategy to Minimize Risk of Exposure to Hazards <i>Ester Marnita Purba (Widyamataram University, Indonesia)</i>
PE-97	The Gate Keeper System in Accessing Health Services, Can It Prevent Liver Failure Patients from Out of Pocket? <i>Helen Try Juni Asti (Cendrawasih University, Indonesia)</i>
PE-98	Genomic Characteristics of Hepatocellular Carcinoma Patients with Response to Sorafenib <i>Sun Young Yim (Korea University, Korea)</i>
PE-99	Chemoprotective Effect of Crocetin against Hepatocellular Carcinoma via Interaction of Gut Microbiota and Biochemical Mechanism <i>Vikas Kumar (Sam Higginbottom University, India)</i>
PE-100	Differential Expression of Telomerase Reverse Transcriptase and Cytokines in Male and Female Patients with Hepatocellular Carcinoma <i>Jin Seoub Kim (The Catholic University of Korea, Korea)</i>
PE-101	Effects of Mesenchymal Stem Cell through the Activation of Liver Sinusoidal Endothelial Cell in Hepatic Progenitor Cell <i>Seul Ki Han (Yonsei University Wonju, Korea)</i>
PE-102	The Effect of Fecal Material Transplantation on Hepatic and Brain Diseases in a Non-Human Primate Model: Several Considerations for Future Application to Liver Disease Patients <i>Seok-Hwan Kim (Chungnam National University, Korea)</i>
PE-103	Status of Blood Transfusion in Liver Surgery in Korea: A National Population-Based Study Using the National Health Insurance Service Database <i>Seonju Kim (Hanyang University, Korea)</i>
PE-104	Machine Learning Models for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Viral Hepatitis B Infection <i>Roongruedee Chaiteerakij (Chulalongkorn University, Thailand)</i>

Liver Cancer: Non-Therapeutic Aspects

PE-105	The Specificity of the Liver Cancer Marker PIVKA II Assay <i>Tsend-Ayush Erdenetsetseg (Mongolian National University, Mongolia)</i>
PE-106	Compliance of the Screening for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B or C <i>Hyunwoo Oh (Eulji University, Korea)</i>
PE-107	Association of Physical Activity, Including Amount and Maintenance, with Risk of Hepatocellular Carcinoma among Patients with Diabetes <i>Mi Na Kim (Yonsei University, Korea)</i>
PE-108	The Prognostic Efficacy of Biliary Drainage in HCC with Bile Duct Invasion: A Multicenter Retrospective Cohort Study with Propensity Score Matching <i>Keungmo Yang (The Catholic University of Korea, Korea)</i>

Liver Cancer: Non-Therapeutic Aspects

PE-109	Clinical Characteristics and Risk Factors of Extrahepatic Recurrence after Hepatectomy of Hepatocellular Carcinoma without Intrahepatic Hepatocellular Carcinoma: A Multi-Institutional 15-Year Observational Study <i>Ara Kyung (Chonnam National University, Korea)</i>
PE-110	A Refined Prediction Model for Overall Survival in Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma <i>Hae Lim Lee (The Catholic University of Korea, Korea)</i>
PE-111	Fiver-Year On-Treatment Parameters-Based Model Predicts Subsequent Hepatocellular Carcinoma in Entecavir/Tenofovir-Treated Patients <i>Yeonjung Ha (CHA University, Korea)</i>
PE-112	Factors Associated with Late HCC Detection in Patients with Chronic Liver Disease under Regular Surveillance <i>Sangmi Jang (Inha University, Korea)</i>
PE-113	Surveillance of Hepatocellular Carcinoma Is Cost-Effective in Chronic Viral Hepatitis Patients in Korea <i>Young Youn Cho (Chung-Ang University, Korea)</i>
PE-114	Comparison of Diagnostic Efficacy between ASAP Score and GALAD Score for Detection of Early-Stage Hepatocellular Carcinoma: A Multicenter Case-Control Study <i>Tian Yang (Navy Medical University, China)</i>
PE-115	A Better Prognosis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Tenofovir Compared with Entcavir <i>Sung Won Chung (University of Ulsan, Korea)</i>

Liver Cancer: Treatment

PE-116	Proper Position of Single and Large (≥ 5 cm) Hepatocellular Carcinoma in Barcelona Clinic Liver Cancer Stage <i>Hyo-Sin Kim (Chonnam National University, Korea)</i>
PE-117	How to Cure Depression in Patients after Chronic Liver Disease or Liver Transplantation? Systematic Literature Review <i>Zulfa Saumia (Universitas Jambi, Indonesia)</i>
PE-118	Longterm Efficacy of HAIC with 3D-CRT for Unresectable Advanced Hepatocellular Carcinoma Complicated by Major Vascular Tumor Thrombosis <i>Joji Tani (Kagawa University, Japan)</i>
PE-119	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence and Simple Scoring System for Prediction of Hepatocellular Carcinoma Occurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: AKLD Group Study <i>Shungo Kimura (Kagawa University, Japan)</i>
PE-120	Clinical Trial in Asian Patients Liver Cancer: Systematic Review <i>Ferza Alfath (Alumnus Universitas, Indonesia)</i>

Liver Cancer: Treatment

PE-121	Prognostic Impact of the Progression of Lung Metastasis after the First Cycle of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma <i>Jiwon Yang (University of Ulsan, Korea)</i>
PE-122	Phytochemicals-Based Drug Designing for Liver Cancer: A Molecular Docking Study <i>Preeti Puranik (Shri Jain Diwakar Mahavidyalaya, India)</i>
PE-123	Developing of Artificial Intelligence on Liver Cancer: Systematic Review <i>Muhammad Irzaq (Alumnus Universitas, Indonesia)</i>
PE-124	Financial Burden of Liver Cancer: Problem and Solution for Liver Cancer Patient <i>Fitri Kurnia (Muhammadiyah University, Indonesia)</i>
PE-125	A Comparative Study of Atezolizumab plus Bevacizumab and Transarterial Chemoembolization plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis <i>Soon Kyu Lee (The Catholic University of Korea, Korea)</i>
PE-126	Therapeutic Efficacy of Radiofrequency Ablation with D-Sorbitol in Animal Livers <i>Ryosuke Imado (Kagawa University, Japan)</i>
PE-127	A Case of Seeding along the Needling Tract Following Radiofrequency Ablation for Hepatocellular Carcinoma <i>Ga Ram You (Chonnam National University, Korea)</i>
PE-128	A Case of Thrombotic Event Associated with Long-Term Usage of Combination Therapy of Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma Patient <i>Ga Ram You (Chonnam National University, Korea)</i>
PE-129	Effectiveness and Safety of Sorafenib 400 mg Initial Dose Compared with Sorafenib 800 mg Initial Dose on Survival in Patients with Advanced and Intermediate Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis <i>Roland Helmizar (Baiturrahmah University, Indonesia)</i>
PE-130	Sorafenib versus Lenvatinib after Atezolizumab/Bevacizumab Failure in Patients with Advanced Hepatocellular Carcinoma: A Real-World Multicenter Study <i>Young Eun Chon (CHA University, Korea)</i>
PE-131	The Efficacy and Safety of Atezolizumab & Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: The Real World Data <i>Sung Hwan Yoo (Yonsei University, Korea)</i>
PE-132	In-Depth External Validation of Subclassification System of Hepatocellular Carcinoma with Macroscopic Vascular Invasion Treated with Combined Transarterial Chemoembolization and Radiotherapy as a First-Line Treatment <i>Jeong Il Yu (Sungkyunkwan University, Korea)</i>
PE-133	Comparative Analysis of Combination Therapy (Atezolizumab + Bevacizumab) and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center Study <i>Ji Hoon Kim (The Catholic University of Korea, Korea)</i>
PE-134	Survival Prediction Model for Patients with Hepatocellular Carcinoma and Extrahepatic Metastasis Based on XGBoost Algorithm <i>Jihye Lim (The Catholic University of Korea, Korea)</i>

Liver Cancer: Treatment

PE-135	Clinical Characteristics and Prognostic Factors of 80 Years or Older Patients with Hepatocellular Carcinoma <i>Hoon Gil Jo (Wonkwang University, Korea)</i>
PE-136	Recurrence of Hepatocellular Carcinoma in Non-Cirrhotic Patients with Non-Alcoholic Fatty Liver Disease versus Hepatitis B Infection <i>Young-Joo Jin (Inha University, Korea)</i>
PE-137	Growth Rate of Untreated HCC in Patients with over 80 Years of Age <i>Dong Yune Ahn (Wonkwang University, Korea)</i>
PE-138	Efficacy Comparison of First-Line Therapies of Unresectable Hepatocellular Carcinoma in Older Age Patients <i>Ahlim Lee (The Catholic University of Korea, Korea)</i>
PE-139	Efficacy of Cabozantinib after Sorafenib Treatment for Advanced Hepatocellular Carcinoma <i>Ahlim Lee (The Catholic University of Korea, Korea)</i>
PE-140	Machine Learning Model for Driver Gene Identification Reveals Roles of Interferon Stimulated Genes in Sorafenib Resistance of HCC <i>Deok Hwa Seo (The Catholic University of Korea, Korea)</i>
PE-141	Long-Term Outcomes of Liver Transplantation for Patients with Hepatocellular Carcinoma beyond Milan Criteria: A Multicenter Cohort Study <i>Heechul Nam (The Catholic University of Korea, Korea)</i>
PE-142	Impact of Prior TACE History on the Outcome of HCC Patients Undergoing TKI versus ICI: A Real-World Analysis <i>Kwon Yong Tak (KAIST, Korea)</i>
PE-143	The Utility of PIVKA-II as a Biomarker for Treatment Response in Hepatocellular Carcinoma <i>Charmaine Patricia Y. Varquez (Makati Medical Center, Philippines)</i>
PE-144	Utilization of Community-Based Health Centers (Puskesmas) to Improve Accessibility of Health Services for Liver Patients <i>Rosinta Hotmaida Pebrianti Purba (Learning-Up Institute, Indonesia)</i>
PE-145	Aging in Place for Elderly Undergo Liver Transplantation: How Informal Care Could Help Maintaining Higher Quality of Life? <i>Ester Marnita Purba (Widyamataram University, Indonesia)</i>
PE-146	Multidimensional Quality of Life after Pediatric Liver Transplantation: Luck or Measurable Achievement? <i>Ester Marnita Purba (Widyamataram University, Indonesia)</i>
PE-147	Outcomes between Surgical Resection and Transarterial Chemoembolization in Patients with Multifocal BCLC-A and Child-Pugh B <i>Jiwon Yang (University of Ulsan, Korea)</i>
PE-148	Comparison of Clinical Outcome between Nivolumab and Regorafenib as Second-Line Systemic Therapies after Sorafenib Failure in Patients with Advanced Hepatocellular Carcinoma <i>Jae Seung Lee (Yonsei University, Korea)</i>

Liver Cancer: Treatment

PE-149	Statin on the Recurrence of Hepatocellular Carcinoma after Liver Transplantation: An Illusion Revealed by Exposure Density Sampling <i>Deok-Gie Kim (Yonsei University, Korea)</i>
PE-150	Acute Kidney Injury Predicts Poor Prognosis in Hepatocellular Carcinoma Patients with Spontaneous Bacterial Peritonitis <i>Min-Kyoung Kim (Chosun University, Korea)</i>
PE-151	Prognostic Value of Serum Alpha-Fetoprotein Level for Patients Undergoing Hepatectomy for Early-Stage (BCLC Stage 0/A) Hepatocellular Carcinoma: A Large Multicenter Analysis <i>Tian Yang (Navy Medical University, China)</i>
PE-152	Preoperative and Postoperative Variables for Redicting Extrahepatic Metastasis of Hepatocellular Carcinoma after Curative Surgical Resection <i>In Gun Yeo (Jeonbuk National University, Korea)</i>
PE-153	Efficacy of Renshenguben Oral Solution for Cancer-Related Fatigue among Patients with Advanced-Stage Hepatocellular Carcinoma: A Prospective Multicenter Cohort Study <i>Tian Yang (Navy Medical University, China)</i>
PE-154	Efficacy and Feasibility of Perioperative Radiotherapy for HCC: A Quality-Based Systematic Review and Meta-Analyses <i>Chai Hong Rim (Korea University, Korea)</i>
PE-155	Effects of Main Portal Vein Tumor Thrombi (PVTT) and Previous Locoregional Therapy (TACE) in Advanced Hepatocellular Carcinoma Treated with Lenvatinib <i>Jaekyung Cheon (CHA University, Korea)</i>
PE-156	Effect of Frailty on Short- and Long-Term Outcomes Following Hepatectomy for Elderly Patients with Hepatocellular Carcinoma: A Multicentre Study <i>Tian Yang (Navy Medical University, China)</i>
PE-157	Development and Validation of Nomograms to Predict Survival and Recurrence Following Hepatectomy for Intermediate/Advanced Hepatocellular Carcinoma: A Multi-Institutional Observational Study <i>Tian Yang (Navy Medical University, China)</i>
PE-158	Comparison of Long-Term Clinical Outcomes between Radiofrequency Ablation and Hepatic Resection in Patients with Single Small (≤ 2 cm) Hepatocellular Carcinoma <i>Young Mi Hong (Pusan National University, Korea)</i>
PE-159	Case Study: Atezolizumab plus Bevacizumab Regimen and Possible Higher Risk of Brain Hemorrhage <i>Bangju Kim (Kosin University, Korea)</i>
PE-160	Serum AFP Response as a Preoperative Prognostic Indicator in Unresectable Hepatocellular Carcinoma with Salvage Hepatectomy following Conversion Therapy <i>Tian Yang (Navy Medical University, China)</i>

Liver Cirrhosis and Portal Hypertension

PE-161	Non-Invasive Test for Estimation of Liver Fibrosis <i>Khishgee Duinkherjav (Intermed Hospital, Mongolia)</i>
--------	---

Liver Cirrhosis and Portal Hypertension

PE-162	Clinical Effectiveness of Human Albumin in Liver Cirrhosis: A Meta-Analysis Update <i>Yuhan Liu (Takeda International Trading Co., Ltd, China)</i>
PE-163	The Prediction of Liver Decompensation Using Hepatic Collagen Deposition Assessed by Computer-Assisted Image Analysis with Masson's Trichrome Stain <i>Kyung Hun Park (SoonchunHyang University, Korea)</i>
PE-164	Machine Learning-Based Classification System for Predicting Liver Fibrosis in Hepatitis C Patients: Enhancing Accuracy and Reducing Invasive Procedures <i>Rifaldy Fajar (Karlstad University, Sweden)</i>
PE-165	Prevalence of Helicobacter Pylori Infection among Patients with Liver Cirrhosis in Makassar: A Descriptive Study <i>Muhammad Ranushar (Hasanuddin University, Indonesia)</i>
PE-166	Recurrence of Idiopathic Portal Hypertension after Liver Transplantation with Portal Vein Thrombosis and Splenectomy: A Case Report and Review of the Literature <i>Aibar Aginbay (National Research Oncology Center, Kazakhstan)</i>
PE-167	Enhancing Bioavailability of Furosemide for the Management of Liver Cirrhosis Using Self Nano Emulsifying Drug Delivery System <i>Pankajkumar Yadav (SHUATS, India)</i>
PE-168	The Characteristics of Patients with Liver Cirrhosis Who Develop Portal Hypertensive Gastropathy <i>Ha Linh (103 Cam Khe Clinic, Vietnam)</i>
PE-169	Wearable Technology for the Management of Liver Cirrhosis and Hypertension: A New Tool <i>Manvendra Singh (HMFA-MIET, India)</i>
PE-170	Evaluation of Spleen Stiffness-Spleen Size-to-Platelet Ratio Score (SSPS) as Non-Invasive Predictor of Oesophageal Varices in Patients with Cirrhosis of Liver <i>Abhishek Kumar Verma (Kalinga Institute of Medical Sciences, India)</i>
PE-171	Risk Factor of Portal Hypertension in Children with Biliary Atresia <i>Firyal Nadiyah Rahmah (Universitas Airlangga, Indonesia)</i>
PE-172	Characteristics of Cirrhotic Patients in Indonesia: A Literature Review <i>Hadi Saputra (Muhammadiyah Surakarta University, Indonesia)</i>
PE-173	Direct/Total Bilirubin Ratio as a Risk Factor of Portal Hypertension <i>Firyal Nadiyah Rahmah (Universitas Airlangga, Indonesia)</i>
PE-174	Evaluation of Spleen Stiffness and Liver Stiffness as Non-Invasive Predictors of Oesophageal Varices in Patients with Cirrhosis of Liver <i>Abhishek Kumar Verma (Kalinga Institute of Medical Sciences, India)</i>
PE-175	The Efficacy and Safety of Endoscopic Variceal Ligation versus Propranolol as Prophylaxis of First Variceal Bleeding in Patients with Liver Cirrhosis <i>Sung Hwan Yoo (Yonsei University, Korea)</i>

Liver Cirrhosis and Portal Hypertension

PE-176	TIPS Is More Useful for the Treatment of Intractable Variceal Bleeding in Patients with Total Gastrectomy <i>Kyeongsoo Kim (Wonkwang University, Korea)</i>
PE-177	Prognostic Value of Nutritional Index in Patients with Decompensated Cirrhosis: A Single-Center Cohort Study <i>Heechul Nam (The Catholic University of Korea, Korea)</i>
PE-178	Successful Treatment of Refractory Hepatic Encephalopathy with Two Sessions of Plug-Assisted Retrograde Transvenous Obliteration: A Case Report <i>Yong Soo Song (Chonnam National University, Korea)</i>
PE-179	Acute Kidney Disease Is Common and Associated with Poor Clinical Outcomes in Cirrhotic Patients with Acute Kidney Injury <i>Jeong Eun Song (Daegu Catholic University, Korea)</i>
PE-180	Risk Factors of Bloodstream Infection after Endoscopic Injection of N-Butyl-2-Cyanoacrylate for Gastric Variceal Bleeding <i>Ui Hyung Kim (The Catholic University of Korea, Korea)</i>
PE-181	Prediction of Portal Hypertension Using Non-Invasive Parameters: Using 670 Cirrhosis Patients' Data <i>Jong Wan Lim (Yonsei University, Korea)</i>
PE-182	Different Risk Factors of Clinical Outcomes between Variceal Bleeding and Non-Variceal Gastrointestinal Bleeding in Acutely Decompensated Cirrhosis <i>Ji Won Park (Hallym University, Korea)</i>
PE-183	Safety of Warfarin and Direct Oral Anticoagulants in Liver Cirrhosis with Atrial Fibrillation <i>Yeo Wool Kang (Dong-A University, Korea)</i>
PE-184	Different Role of Organ Failure according to Clinical Presentation in Acutely Decompensated Cirrhosis <i>Sung-Eun Kim (Hallym University, Korea)</i>
PE-185	MicroRNA-101-3p: A Dual Function Regulator in the Therapeutic Potential of Human Bone Marrow-Derived Mesenchymal Stem Cells for Liver Fibrosis <i>Seawon Hwang (The Catholic University of Korea, Korea)</i>
PE-186	Development of a Self-Management Scale for Patients with Liver Cirrhosis <i>Oh Young Kwon (Yonsei University College of Nursing, Korea)</i>
PE-187	Platelet/Spleen Ratio as Non-Invasive Predictor of Esophageal Varices in Cirrhotics <i>Rakesh Garlapati (Kurnool Medical College, India)</i>
PE-188	Spleen Stiffness as a Non-Invasive Test to Evaluate Esophageal Varices Needing Treatment and Portal Pressure Gradient in Liver Cirrhosis <i>Sang Gyune Kim (Soonchunhyang University, Korea)</i>

NAFLD	
PE-189	The Role of Vitamin E in the Treatment of Non-Alcoholic Steatohepatitis (NASH) <i>Mohamed Shafi Bin Mahboob Ali (Advanced Medical and Dental Institute, Malaysia)</i>
PE-190	Gut Microbiota and Leaky Gut in a High-Fat Diet-Induced NASH Animal Model <i>Sora Kirihara (Okayama University, Japan)</i>
PE-191	Cholesterol Crystals Aggravate NASH by Activating the NLRP3 Inflammasome <i>Hinako Nakayama (Okayama University, Japan)</i>
PE-192	Uncommon Culprit of a Common Disease: A Case of a Drug Induced Steatohepatitis Secondary to Cyproterone Acetate, Ethinylestradiol <i>Edzel M. Magtoto (De Los Santos Medical Center, Philippines)</i>
PE-193	Association of NAFLD with COVID-19 Outcomes: A Meta-Analysis <i>Ruby Singh (Independent Researcher, India)</i>
PE-194	Untangling the Role of Proinflammatory Cytokines in T2DM Patients with Non-Alcoholic Fatty Liver Disease <i>Rajiv Nehra (RD Medical College, India)</i>
PE-195	Response of Mediators of Inflammation in Liver NAFLD <i>Manju Rani (CHC, India)</i>
PE-196	The Clinical Usefulness of the Visceral Fat Thickness Measured by Abdominal Ultrasonography in Patients with Non-Alcoholic Fatty Liver Disease <i>Young Chang (Soonchunhyang University, Korea)</i>
PE-197	Liver Disease Treatment Effect of Metformin and Empagliflozin Combination in NASH Model <i>Mi Ra Lee (Yonsei University Wonju, Korea)</i>
PE-198	Chemotherapy Induced Fatty Liver in Ovarian Cancer <i>Harshita Dubey (All India Institute of Medical Sciences, India)</i>
PE-199	Clinical Implication of Hepatitis B Virus Infection with Non-Alcoholic Fatty Liver Disease in Primary Care Institution <i>Min Seong Kim (Millennium Seoul IM Clinic, Korea)</i>
PE-200	Effects of Simvastatin Administration on the Severity of Steatosis in the Liver of Wistar Rats Induced by Dyslipidemia <i>Adi Nugraha (Universtias Islam, Indonesia)</i>
PE-201	Discovery Biomarker to Optimize Obeticholic Acid Treatment for Non-Alcoholic Fatty Liver Disease <i>Seung Min Lee (Hanyang University, Korea)</i>
PE-202	Synergistic Effect of Hepatic Steatosis and Diabetes Mellitus on Significant Liver Fibrosis <i>Won Sohn (Sungkyunkwan University, Korea)</i>

NAFLD	
PE-203	Risk Factors for Significant Fibrosis in Non-Obese Asian Patients with Non-Alcoholic Fatty Liver Disease <i>Hyo young Lee (Eulji University, Korea)</i>
PE-204	The Efficacy of N-Acetylcysteine for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies with Comprehensive Transcriptomic Analysis <i>Keungmo Yang (The Catholic University of Korea, Korea)</i>
PE-205	Association of Controlled Attenuation Parameter and Liver Stiffness with Coronary Heart Disease in Patients with Diabetes Mellitus <i>Oh Sang Kwon (Gachon University, Korea)</i>
PE-206	Impact of Myosteatosis on Fibrosis Progression in Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Single Center, Prospective Study <i>Kyewhon Kim (Yeungnam University, Korea)</i>
PE-207	Impact of Visceral Adiposity for Coronary Artery Calcification Progression in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: Multicenter Cohort Study <i>Jung Gil Park (Yeungnam University, Korea)</i>
PE-208	MiR-4449-Merlin-TAZ Axis Regulates Fibrosis Progression in Non-Alcoholic Steatohepatitis <i>Yoonseok Lee (Korea University, Korea)</i>
PE-209	Preventive Effect of Empagliflozin and Ezetimibe on Hepatic Steatosis in Adults and Murine Models <i>Dong Yun Kim (Yonsei University Wonju, Korea)</i>
PE-210	L. Plantarum Ameliorates NASH-Related Inflammation via Upregulating L-Arginine Production <i>Dong Yun Kim (Yonsei University, Korea)</i>
PE-211	ALT/AST Ratio: The Useful Predictive Marker for Insulin Resistance <i>Dong Kyun Koh (Yonsei University, Korea)</i>
PE-212	The Effect of Thyroid Function on the Deterioration of NAFLD in a Prospective Cohort <i>Sae Kyung Joo (Seoul National University, Korea)</i>
PE-213	Magnetic Resonance Imaging-Proton Density Fat Fraction Correlates with Histologic Proven Hepatic Steatosis in Obese Patients: Single Center Study of Korea <i>Kwang Il Seo (Kosin University, Korea)</i>
PE-214	Comparison of Efficacy between Liraglutide and Phentermine/Topiramate in Obese Patients with Non-Alcoholic Fatty Liver Disease <i>Sung Jun Park (CHA University, Korea)</i>
PE-215	Extrahepatic Malignancies in Metabolic Dysfunction-Associated Fatty Liver Disease: A Nationwide Cohort Study <i>Moon Haeng Hur (Seoul National University, Korea)</i>
PE-216	Changes in Liver Stiffness and Controlled Attenuation Parameters of Transient Elastography according to Weight Change in Non-Alcoholic Fatty Liver Disease <i>Seong Kyun Na (Inje University, Korea)</i>

NAFLD

PE-217	Essential Adolescent Lifestyle: Coffee Drinking Habit Contributes to Liver Disease: Evidence from Asia <i>Vivi Usmayanti (Universitas Sriwijaya, Indonesia)</i>
PE-218	Severity of Fatty Liver Is Highly Correlated with the Risk of Hypertension and Diabetes: A Cross-Sectional and Longitudinal Cohort Study <i>Chin-I Shih (Kaohsiung Veterans General Hospital, Taiwan)</i>
PE-219	Diagnostic Performance of an Enhanced Liver Fibrosis Panel on the Identification of Fibrosis in Patients with High-Risk Non-Alcoholic Fatty Liver Disease <i>Yeo Wool Kang (Dong-A University, Korea)</i>
PE-220	Risk Factors for Significant Fibrosis in Non-Alcoholic Fatty Liver Disease with a Low FIB-4 Level <i>Won Sohn (Sungkyunkwan University, Korea)</i>
PE-221	Differentiation of Liver Fibrosis Risk in Non-Alcoholic Fatty Liver Disease Patients Using Serum Mac-2 Binding Protein Glycosylation Isomer <i>Minna Kim (Dong-A University, Korea)</i>
PE-222	NAFLD in Pediatrics <i>Hong Koh (Yonsei University, Korea)</i>
PE-223	Comparison of Transient Elastography and Shear Wave Elastography in Assessment of Liver Fibrosis in Egyptian Patients with NAFLD: A Single Center Experience <i>Ahmed El Fayoumi (Menoufia University, Egypt)</i>
PE-224	Age-Specific Prevalence of Vitamin D Insufficiency in MAFLD Determined by Fatty Liver Index in Korean Adults <i>Kwang Min Kim (Sungkyunkwan University, Korea)</i>

Others

PE-225	Liver Transplant <i>Javad Alizargar (Kashan University, Iran)</i>
PE-226	A Nationwide Study of Key Indicators for Eliminating Viral Hepatitis B and C in Korea <i>Chang Hun Lee (Jeonbuk National University, Korea)</i>
PE-227	Improving Hepatocellular Carcinoma Diagnosis from CT Scan Images with the Probabilistic Radial Basis Function Network Algorithm <i>Sahnaz Vivinda Putri (International University, Indonesia)</i>
PE-228	The Development of Viral Hepatitis in Asia: Systematic Review <i>Devi Yulia Rahmi (Universitas Andalas, Indonesia)</i>
PE-229	Study about Autoimmune Liver Disease in Asian Children: A Systematic Review <i>Ferza Alfath (Alumnus Universitas, Indonesia)</i>

Others

PE-230	Live Donor Liver Transplantation (LDLT) in Asia: Systematic Review <i>Devi Yulia Rahmi (Universitas Andalas, Indonesia)</i>
PE-231	Global Interest in Hepatitis B Viral Infection, Risk Factors, Neurological Sequelae, and Neuroimaging Tools in Neonatal Jaundice Using Google Trends <i>Albert Dayor Piersson (University of Cape Coast, Ghana)</i>
PE-232	The Clinical Course and Outcomes of Patients with COVID-19 Given Ursodeoxycholic Acid, Transmetil or Silymarin: A Retrospective Cross-Sectional Single Center Study <i>Godofredo Vistal (St. Luke's Medical Center, Philippines)</i>
PE-233	Analysis of Total Protein Concentration and Antioxidant Activity in Pesticide-Highly Contaminated Rice <i>Nisrin Abd Kadir (Universiti Malaysia Terengganu, Malaysia)</i>
PE-234	Randomized Controlled Trial: The Effect of Oral Methylprednisolone versus Placebo to Reducing Level Liver Enzyme in Cholestasis Infants <i>Anindya Kusuma Winahyu (Dr. Soetomo General Hospital, Indonesia)</i>
PE-235	Bile Acids Are Associated with Drug Induced Liver Injury (DILI) in Patients on Anti-Tuberculous Therapy (ATT) <i>Ashok Kumar (PGIMER, India)</i>
PE-236	A Case of Concomitant Liver and Brain Abscesses Caused by Streptococcus Intermedius <i>Gum Mo Jung (Jesus Hospital, Korea)</i>
PE-237	High Serum IL-15 Level and Intrahepatic NKG2D Expression Are Associated with the Cholestatic Liver Injury in Patients with Drug-Induced Liver Injury <i>Ji Won Han (The Catholic University of Korea, Korea)</i>
PE-238	High Serum CXCL13 Level Is Associated with the Severe Cholestatic Liver Injury in Patients with Drug-Induced Liver Injury <i>Ji Won Han (The Catholic University of Korea, Korea)</i>
PE-239	The Effect of Turmeric Powder on Liver Enzyme Levels in Male Wistar Rats Induced Hyperlipidemia <i>Adi Nugraha (Universitas Islam Indonesia, Indonesia)</i>
PE-240	The Role of M2BPGi for Screening Advanced Hepatic Fibrosis in Elderly Patients <i>Hoon Gil Jo (Wonkwang University, Korea)</i>
PE-241	Utilizing Data Mining Techniques to Develop Accurate Classification Models for Hepatitis C Virus Infection Diagnosis <i>Rifaldy Fajar (Department of Mathematics and Computer Science, Sweden)</i>
PE-242	Empowering Community Health Workers to Enhance Hepatitis Management in Underprivileged Families: A Community-Based Intervention in East Java, Indonesia <i>Sahnaz Vivinda Putri (International University Semen Indonesia, Indonesia)</i>
PE-243	Gemigliptin Alleviates Succinate Induced Endoplasmic Reticulum Stress and Activation of Hepatic Stellate Cells <i>Dae Hee Choi (Kangwon National University, Korea)</i>

Others

PE-244	Is It True That Religiosity Increases Survival Rate in Patients with Liver Failure? <i>Helen Try Juni Asti (Cendrawasih University, Indonesia)</i>
PE-245	Increased Risk of Osteoporotic Fracture in Patients with Autoimmune Hepatitis <i>Jihye Lim (The Catholic University of Korea, Korea)</i>
PE-246	Serum CCL4 as a Prognostic Biomarker for Drug-Induced Liver Injury <i>Hee Sun Cho (The Catholic University of Korea, Korea)</i>
PE-247	Metabolic Disorders Are Associated with Drug-Induced Liver Injury during Anti-Tuberculosis Treatment <i>Kyeong Ah Jang (The Catholic University of Korea, Korea)</i>
PE-248	Gamma-Glutamyl Transferase and Risk of All-Cause and Disease-Specific Mortality in People with Diabetes: A Nationwide Cohort Study <i>Su Jong Yu (Seoul National University, Korea)</i>
PE-249	A Case of Successful Hemostasis of Rectal Variceal Bleeding with Coil Embolization <i>Deoksu Lee (Chosun University, Korea)</i>
PE-250	The Effect of MELD 3.0 Score on the Disparities between Patients with and without Hepatocellular Carcinoma in Korea <i>Kunhee Kim (Yonsei University, Korea)</i>
PE-251	Personalized Antiviral Drug Selection in Chronic Hepatitis B Patients Using a Machine Learning Model: A Multinational Study <i>Moon Haeng Hur (Seoul National University, Korea)</i>
PE-252	Extrahepatic Malignancies and Antiviral Drugs for Chronic Hepatitis B: A Nationwide Cohort Study <i>Moon Haeng Hur (Seoul National University, Korea)</i>
PE-253	Comparison of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials <i>Moon Haeng Hur (Seoul National University, Korea)</i>
PE-254	Chemogenetic Stimulation of the Parasympathetic Nervous System Lowers Hepatic Lipid Accumulation and Inflammation in a Non-Alcoholic Steatohepatitis Mouse Model <i>Moon Haeng Hur (Seoul National University, Korea)</i>
PE-255	Morphological Architectures of Patient-Derived Hepatocellular Carcinoma Organoids with GSK3-Beta Expression Dependent Variability according to Lenvatinib Resistance <i>Kyungjoo Cho (Yonsei University, Korea)</i>
PE-256	Clusterin Inhibits Liver Inflammation and NLRP3 Inflammasome <i>Hye-Young Seo (Keimyung University, Korea)</i>
PE-257	Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with Increased Risk of Liver-Related Complications: A Nationwide Cohort Study <i>Hyunjae Shin (Seoul National University, Korea)</i>

Others	
PE-258	Deletion of Mixed Lineage Kinase Domain Like Pseudokinase Aggravate Chronic Alcohol Induced Liver Injury via Increasing Apoptosis <i>Eileen L. Yoon (Hanyang University, Korea)</i>
PE-259	Diagnostic Performance of NAFLD Fibrosis Score in Lean NAFLD <i>Eileen L. Yoon (Hanyang University, Korea)</i>
PE-260	Tumor Stage Prediction of Hepatocellular Carcinoma Using APG Beads with Graphene Oxide <i>Hyuk Soo Eun (Chungnam National University, Korea)</i>
PE-261	Macro-Aspartate Aminotransferase in a Patient with Chronic Hepatitis B <i>Nae-Yun Heo (Inje University, Korea)</i>
PE-262	Hepatic Angiosarcoma with Tumor Bleeding Controlled by Embolization <i>Nae-Yun Heo (Inje University, Korea)</i>
PE-263	The Relationship between Fatty Liver Disease and Thyroid Nodules in Primary Care Institution <i>Min Seong Kim (Millennium Seoul Internal Medicine Clinic, Korea)</i>
PE-264	PCKS9 Inhibition Attenuates Steatosis and Inflammation by Ameliorating ER Stress in Non-Alcoholic Fatty Liver Disease Mouse Model <i>Myeong Jun Song (The Catholic University of Korea, Korea)</i>
PE-265	Acute Respiratory Distress Syndrome due to Severe Pneumonitis after Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma Treatment: A Case Report <i>Jae Hyun Yoon (Chonnam National University, Korea)</i>
PE-266	Extrahepatic Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation or Surgery: Multi-Institutional Study Using Propensity Score Matched Analysis <i>Jae Hyun Yoon (Chonnam National University, Korea)</i>
PE-267	Sarcopenia in Chronic Liver Disease: Easy to Diagnose? <i>Seong Hee Kang (Korea University, Korea)</i>
PE-268	Comparison of Magnetic Resonance Elastography and Transient Elastography to Detect Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis <i>Seong Hee Kang (Korea University, Korea)</i>
PE-269	The Significance of Radical Resection in T2 GB Cancer <i>Yoonkyung Woo (The Catholic University of Korea, Korea)</i>
PE-270	Metabolic Dysfunction-Associated Fatty Liver Disease Criteria Better Identify Subjects with High-Risk Fatty Liver Disease: A Nationwide Study <i>Ho Soo Chun (Ewha Womans University, Korea)</i>
PE-271	Risk Stratification According to Sarcopenic and Metabolic Status among Overweight/Obese Subjects with Metabolic Dysfunction-associated Fatty Liver Disease <i>Ho Soo Chun (Ewha Womans University, Korea)</i>

Others	
PE-272	The Density of Portal T-Cell Infiltration Effects Clinical Outcomes in Chronic Hepatitis GVHD after Allogeneic Stem Cell Transplantation: A Comparison to Autoimmune Liver Diseases <i>Soon Kyu Lee (The Catholic University of Korea, Korea)</i>
PE-273	The Effect of Fecal Material Transplantation on Hepatic and Brain Diseases in a Non-Human Primate Model: Several Considerations for Future Application to Liver Disease Patients <i>Seok-Hwan Kim (Chungnam National University, Korea)</i>
PE-274	Ultrasound-Based Deep Learning Model for Detection and Classification of Focal Liver Lesions <i>Seung Kak Shin (Gachon University, Korea)</i>
PE-275	Clinical and Molecular Characteristics of Pathologic Subtype in Cholangiocarcinoma <i>Keun Soo Ahn (Keimyung University, Korea)</i>
PE-276	Autoimmune Hepatitis after Anti-SARS-CoV-2 Vaccination: Systematic Review and Meta-Analysis <i>Hye Won Lee (Yonsei University, Korea)</i>
PE-277	Real-World Efficacy and Safety of Cabozantinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis <i>Yeong Hak Bang (University of Ulsan, Korea)</i>
PE-278	Gene Regulatory Network Analysis on snRNAseq Revealed Key Regulators for Hepatocellular Carcinoma Progression <i>Jeayeon Park (Seoul National University, Korea)</i>
PE-279	Rare Recurrence of Hepatic Encephalopathy Associated with Embolization of Extrahepatic Portosystemic Shunt in Patients with Recurrent of Hepatic Encephalopathy <i>Jin Soo Kim (Chungbuk National University, Korea)</i>
PE-280	Diagnostic Performance of Fibrosis-4 Index and NAFLD Fibrosis Score in at-Risk Group from Low Prevalence Population <i>Eileen L. Yoon (Hanyang University, Korea)</i>
PE-281	Management of Chemotherapy Induced Paranasal Sinus Fistula in Mantle Cell Lymphoma <i>Sathya Veera Merla (All India Institute of Medical Sciences, India)</i>
PE-282	Drug Induced Liver Injury Combined with Severe Cutaneous Adverse Drug Reaction Caused by Celecoxib <i>Jae Jin Lee (Daegu Catholic University, Korea)</i>
PE-283	Liver Transplantation due to Chronic Hepatic Graft-versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: Case Series of 3 Patients <i>Jae-Sung Yoo (The Catholic University of Korea, Korea)</i>
PE-284	Implemented Responses of Viral Hepatitis Elimination in Mongolia <i>Badral Davgasuren (National Center for Communicable Diseases, Mongolia)</i>
PE-285	Liver-Directed Combined Radiotherapy in Locally Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis <i>Jina Kim (Yonsei University, Korea)</i>

Poster Exhibition

Room 4 (3F)

Others

PE-286 Effectiveness of Transarterial Chemoembolization for Early Hepatocellular Carcinoma: Single-Center Experience

Moon Hyung Lee (Kyung Hee University, Korea)



Transportation

All participants have access to the complimentary shuttle bus provided by APASL STC 2023 Busan. The bus will make stops at the designated bus stops listed below. Please note that the schedule may change based on daily traffic conditions.

Day 1. September 21, 2023

Shuttle Bus

Paradise Hotel → BEXCO

Paradise	Haeundae Beach	Dongbaek Island	BEXCO
07:50	07:55	08:00	08:10
08:40	08:45	08:50	09:00
09:30	09:35	09:40	09:50
10:20	10:25	10:30	10:40

BEXCO → Paradise Hotel

BEXCO	Dongbaek Island	Haeundae Beach	Paradise
16:20	16:30	16:35	16:40
17:10	17:20	17:25	17:30
18:00	18:10	18:15	18:20

Shuttle Bus (Non-Stop)

Paradise Hotel → BEXCO

Paradise	BEXCO
08:00	08:15
09:00	09:15
10:00	10:15

Day 2. September 22, 2023

Shuttle Bus

Paradise Hotel → BEXCO

Paradise	Haeundae Beach	Dongbaek Island	BEXCO
06:55	07:00	07:05	07:15
07:55	08:00	08:05	08:15
08:55	09:00	09:05	09:15
09:55	10:00	10:05	10:15

BEXCO → Paradise Hotel

BEXCO	Dongbaek Island	Haeundae Beach	Paradise
16:20	16:30	16:35	16:40
17:10	17:20	17:25	17:30
18:00	18:10	18:15	18:20

Shuttle Bus (Non-Stop)

Paradise Hotel → BEXCO

Paradise	BEXCO
07:00	07:15
08:00	08:15
09:00	09:15
10:00	10:15

Day 3. September 23, 2023

Shuttle Bus

Paradise Hotel → BEXCO

Paradise	Haeundae Beach	Dongbaek Island	BEXCO
06:55	07:00	07:05	07:15
07:55	08:00	08:05	08:15
08:55	09:00	09:05	09:15
09:55	10:00	10:05	10:15

BEXCO → Paradise Hotel

BEXCO	Dongbaek Island	Haeundae Beach	Paradise
12:50	13:00	13:05	13:10

Shuttle Bus (Non-Stop)

Paradise Hotel → BEXCO

Paradise	BEXCO
07:00	07:15
08:00	08:15
09:00	09:15
10:00	10:15

BEXCO → KTX Busan Station

BEXCO	KTX Busan Station
12:50	13:30

Transportation


All participants have access to the complimentary shuttle bus provided by APASL STC 2023 Busan. The bus will make stops at the designated bus stops listed below. Please note that the schedule may change based on daily traffic conditions.



Shuttle Bus (20 min.) Paradise Hotel → BEXCO / BEXCO → Paradise Hotel



Shuttle Bus (Non-Stop, 15 min.) Paradise Hotel → BEXCO / BEXCO → Paradise Hotel



APASL STC 2023 BUSAN

Asian Pacific Association for the Study of the Liver Single Topic Conference

"Toward Elimination of Viral Hepatitis"

BOOTH TOUR

Tour Date: **September 21, 2023**

Lucky Draw Time: **17:40 @ ROOM 1 (1F)**

"Please get stamps from all the participating exhibition booths and bring it to the registration desk (1F)"

2F

Yuhan

Gilead

Abbvie

Daewoong

Celltrion

GC

Roche

Eisai

Astellas

Samil

Dona-A ST

Boryung

Sysmex

CKD

Bukwang

Hanmi

PharmaKing

Ildong



APASL



The Korean Association
for the Study of the Liver



질병관리청
Korea Disease Control and
Prevention Agency, KDCA



3F

Name

Affiliation / Institution



APASL STC 2023 BUSAN

Asian Pacific Association for the Study of the Liver Single Topic Conference

"Toward Elimination of Viral Hepatitis"

BOOTH TOUR

Tour Date: **September 21, 2023**

Lucky Draw Time: **17:40 @ ROOM 1 (1F)**

"Please get stamps from all the participating exhibition booths and bring it to the registration desk (1F)"

Lots will be drawn after ending the last session of the conference.
Absentees will be excluded from the event.



1EA

BALMUDA The Toaster

K05B-WH



1EA

Boss SoundLink Mini II

Luxe Silver



3EA

Starbucks Gift Card

₩ 50,000

APASL STC 2023 BUSAN

Asian Pacific Association for the Study of the Liver Single Topic Conference

"Toward Elimination of Viral Hepatitis"

BOOTH TOUR

Tour Date: **September 22, 2023**

Lucky Draw Time: **17:40 @ ROOM 1 (1F)**

"Please get stamps from all the participating exhibition booths and bring it to the registration desk (1F)"

Yuhan

2F

Gilead

Abbvie

Daewoong

Celltrion

GC

Roche

Eisai

Astellas

Samil

Dona-A ST

Boryung

Sysmex

CKD

Bukwang

Hanmi

PharmaKing

Ildong



APASL



The Korean Association
for the Study of the Liver



질병관리청
Korea Disease Control and
Prevention Agency, KDCA



Han Wha

Name

Affiliation / Institution



APASL STC 2023 BUSAN

Asian Pacific Association for the Study of the Liver Single Topic Conference

"Toward Elimination of Viral Hepatitis"

BOOTH TOUR

Tour Date: **September 22, 2023**

Lucky Draw Time: **17:40 @ ROOM 1 (1F)**

"Please get stamps from all the participating exhibition booths and bring it to the registration desk (1F)"

Lots will be drawn after ending the last session of the conference.
Absentees will be excluded from the event.



1EA

Dyson Supersonic

HD15



1EA

AirPods Pro

2nd generation



3EA

Starbucks Gift Card

₩ 50,000

APASL STC 2023 BUSAN

Asian Pacific Association for the Study of the Liver Single Topic Conference

"Toward Elimination of Viral Hepatitis"

BOOTH TOUR

Tour Date: **September 23, 2023**

Lucky Draw Time: **11:50 @ ROOM 1 (1F)**

"Please get stamps from all the participating exhibition booths and bring it to the registration desk (1F)"

2F

Yuhan

Gilead

Abbvie

Daewoong

Celltrion

GC

Roche

Eisai

Astellas

Samil

Dona-A ST

Boryung

Sysmex

CKD

Bukwang

Hanmi

PharmaKing

Ildong



APASL



The Korean Association
for the Study of the Liver



질병관리청
Korea Disease Control and
Prevention Agency, KDCA



3F

Name

Affiliation / Institution



APASL STC 2023 BUSAN

Asian Pacific Association for the Study of the Liver Single Topic Conference

"Toward Elimination of Viral Hepatitis"

BOOTH TOUR

Tour Date: **September 23, 2023**

Lucky Draw Time: **11:50 @ ROOM 1 (1F)**

"Please get stamps from all the participating exhibition booths and bring it to the registration desk (1F)"

Lots will be drawn after ending the last session of the conference.
Absentees will be excluded from the event.



Galaxy Z Flip5



Galaxy Buds 2 Pro

SM-R510NZWAK00



Starbucks Gift Card

₩ 50,000



**The Asian Pacific Association
for the Study of the Liver**



APASL Oncology 2023

In Search of Silver Bullet for HCC

2023

October

27-28

(Friday) (Saturday)

City: Sendai, Japan

Venue: Hotel Metropolitan Sendai

President:

Yoshiyuki Ueno, M.D., Ph.D.

Professor and Chairman,

Department of Gastroenterology, Faculty of Medicine, Yamagata University, Japan

Scientific Secretariat:

**Department of Gastroenterology,
Faculty of Medicine, Yamagata University, Japan**

Congress Secretariat:

c/o Academia Support Japan

TEL +81-3-6380-0102 FAX +81-3-6380-0103

E-mail info@apasl-oncology2023.org

www.apasl-oncology2023.org



The 33rd Annual Meeting of
the Asian Pacific Association for the Study of the Liver

APASL 2024 Kyoto -The Center of Hepatology

Term
March 27-31, 2024

Venue
ICC Kyoto
-Kyoto International Conference Hall
Kyoto, Japan

President
Shuichiro Shiina M.D.
Professor, Department of Gastroenterology,
Juntendo University, Japan

<https://www.apasl2024kyoto.org/>

Scientific Secretariat ▶ Department of Gastroenterology, Juntendo University, Japan
Congress Secretariat ▶ c/o Academia Support Japan Tel: +81-3-6380-0103 Email: info@apasl2024kyoto.org